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ABSTRACT 
 
Background: Bladder Cancer (BC) is the fifth most incident cancer worldwide. It is 
characterized by a high recurrence rate, probably due to the presence of a small 
population of cells within the tumor, named cancer stem cells (CSCs), responsible for 
therapeutic resistance and relapse after initial therapy. Therefore, new therapeutic 
approaches are needed to eliminate all tumor cells, preventing the tumor recurrence. In 
this context, natural killer(NK) cells-based therapy has emerged as an alternative 
strategy, alone or in combination with other therapeutic modalities, to treat BC. Herein, 
we evaluate the effect of sub-apoptotic concentrations of doxorubicin (DOX) and 
bortezomib (BTZ) in sensitizing tumor BC cell lines to NK-mediated killing, through death 
receptors (Fas and DR5) upregulation.  
Methods: Two BC cell lines (UM-UC3 and HT-1376) and their corresponding CSCs, 
isolated through the sphere-forming assay, were incubated with sub-apoptotic 
concentrations of DOX (0.05µM and 0.1µM) and BTZ (5nM and 10nM) for 24h or 48h to 
measure the gene expression of death receptors, using the qRT-PCR technique. 
Subsequently, a 20h 51chromium release assaywas performed to evaluate the NK-
mediated killing, via death receptors signaling, in pre-treated tumor cells. Additionally, 
qRT-PCR was performed to assess the death receptors expression pattern among 
different stages of BC, using clinical samples. 
Results:Pre-treatment with sub-apoptotic concentrations of DOX and BTZ induces a 
significant upregulation of both death receptors in BC parental cells. Compared to 
untreated cells, the pre-treatment of parental cells with 0.05µM DOX and 0.1nM BTZ 
promotes a significant increase in NK cells anti-tumor response, through a perforin-
independent mechanism. The CSCs population was less responsive to DOX- or BTZ-
induced death receptors upregulation, and consequently less susceptible to NK cells 
mediated killing. Furthermore, death receptors gene expression increases progressively 
with the BC tumor stage. 
Conclusions:Our data demonstrates that a pre-treatment with low concentrations of 
DOX and BTZ sensitizes parental BC tumor cells to NK-mediated killing by inducing an 
XXIV 
 
upregulation of death receptors. The CSCs populations express low basal levels of death 
receptors and is less sensitive to NK cell-mediated killing by death-receptors. 
Altogether these results suggest that a combination of DOX or BTZ with NK-based 
immunotherapy may increase the antitumor efficacy against differentiated BC cells but 
are less effective against CSCs. The expression of death receptors in BC correlates with 
tumor stage and aggressiveness, suggesting that it might be used as a prognostic marker 
in BC. 
 
 
Keywords: Bladder cancer; Doxorubicin; Bortezomib; NK cells; death receptors; Fas; 
DR5; immunotherapy; 
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RESUMO 
 
Introdução:O cancro da bexiga (BC, do inglês bladder cancer)é a quinta neoplasia mais 
comum em todo o mundo. É caracterizado por uma alta taxa de recidiva, provavelmente 
devido à presença de uma pequena população de células, designada de Células 
Estaminais Cancerígenas (CSCs, do inglês Cancer Stem Cells), responsável pela 
resistência à terapêutica e a recidiva após a terapia inicial. Assim sendo, são necessárias 
novas abordagens terapêuticas de modo a eliminar completamente o tumor, 
prevenindo o seu reaparecimento. Neste contexto, a terapia com base em células 
natural killer (NK) tem sido estudada como uma estratégia alternativa, sozinha ou em 
combinação com outras terapias,  para o tratamento do BC. Neste trabalho avaliamos o 
efeito de concentrações sub-apoptóticas de doxorubicina (DOX) e bortezomib (BTZ) na 
sensibilização das células tumorais do BC à morte mediada pelas células NK, através do 
aumento de expressão dos receptores de morte. 
Métodos:Duas linhas celulares de BC (UM-UC3 e HT-1376) assim como as suas 
respectivas CSCs, isoladas através do método de formação de esferas, foram incubadas 
com concentrações sub-apoptóticas de DOX (0.05µM e 0.1µM) E BTZ (5nM e 10nM) 
durante 24h e 48h de modo a medir a expressão génica dos receptores de morte, 
usando a técnica de PCR em tempo real. De seguida foi realizado um ensaio de 
libertação de 51crómio de forma a avaliar a morte mediada pelas células NK, através da 
via dos receptores de morte, em células pré-incubadas com DOX e BTZ. Adicionalmente, 
um ensaio de qRT-PCR, utilizando amostras clínicas, foi elaborado de modo a avaliar o 
padrão de expressão dos receptors de morte nos vários estadios do BC. 
Resultados:O pré-tratamento com concentrações sub-apoptóticas de DOX e BTZ induz 
um aumento significativoda expressão dos receptores de morte nas células parentais do 
BC. Comparando com células não tratadas, o pré-tratamento de células parentais com 
0.05µM DOX e 0.1nM BTZ promove um aumento significativo da resposta anti-tumoral 
das células NK, através de um mecanismo independente da perforina. A população de 
CSCs foi menos sensível à regulação dos receptors de de morte induzida pela DOX e BTZ 
e, consequentemente menos sensível à morte celular mediada pelas células NK. 
XXVI 
 
Conclusão:O nosso estudo demonstra que o pré-tratamento com baixas concentrações 
de DOX e BTZ sensibiliza as células tumorais de BC para a morte mediada pelas células 
NK devido ao aumento da expressão dos receptores de morte. As populações de CSCs 
expressam baixos níveis basais de receptores de morte e são menos sensíveis à morte 
mediada pelas células NK, através destes receptores.No seu conjunto, estes resultados 
sugerem que a combinação de DOX e BTZ com a immunoterapia baseada em células NK  
pode aumentar a eficácia da resposta anti-tumoral contra células parentais mas é menos 
sensível contra CSCs. A expressão de receptores de morte no BC correlaciona-se com o 
estadio e agressividade tumoral, sugerindo que os receptores de morte poderão ser 
usados como marcadores de prognóstico. 
 
Palavras-chave: Cancro da bexiga; Doxorubicina; Bortezomib; células NK; Receptores de 
morte; Fas; DR5; Imunoterapia; 
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1.1 Bladder cancer 
 
1.1.1 Epidemiology 
 
In Western World, bladder cancer (BC) represents the fourth and ninth most 
common cancer in men and women, respectively1. Overall BC is the fifth most incident 
cancer in both sexes, only surpassed by lung and bronchus, colorectal, prostate or breast 
cancers2. 
Although the incidence rates of the 4 major cancer types have been declining 
over the last 20 years, the incidence rate of BC has remained relatively stable2. 
BC appearance is strongly related to age, with the highest rates of incidence 
being in the elderly population. Approximately 66% of BC cases are diagnosed among 
individuals older than 65 years3. 
There are substantial differences in the incidence and severity of BC between 
genders and ethnicities. Men have a higher risk of BC than women in a 3:1ratio. This is 
mainly due to tobacco smoking and occupational exposure to aromatic amines, the 
major risk factors in BC. Furthermore, white population presents a higher risk of BC 
compared to the black population4.  
The prognosis of individuals diagnosed with BC is better in younger ages. Overall, 
the relative 5-years survival after BC diagnosis was described as 72% in men and 67% in 
women. Patients diagnosed at 15-44 years of age present 90% and in patients older than 
75 years of age, the 5-year survival rate drops to 61%5. 
 
 
1.1.2 Etiology 
 
The relationship between BC and potential risk factors that influence bladder 
carcinogenesis has long been studied. The development and progression of BC appear to 
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be multifactorial processes and the contributing factors can be differentiated into 
external exposure and inherited genetic alteration6. 
 
External exposure 
 
The cigarette smoking is recognized as the major risk factor for BC and is 
estimated to account for approximately 66% of new cases of BC in men and 30% cases in 
women in industrialized population. The tobacco smoking has the same effect in men 
and women, as well as in different ethnic populations7. The BC risk is 2-4 times higher in 
smokers than in nonsmokers8,4.  
Tobacco contains aromatic amines, which are excreted renally and exert a 
carcinogenic effect in the entire urinary system. Cessation of smoking can reduce BC risk 
around 30% after 1-4 years of cessation and the decrease in risk continues with time 
until 60% after 25 years of cessation. People who stopped smoking also demonstrate 
improvements on outcome and overall survival of BC patients. Environmental exposure 
to smoke during childhood or adulthood has been associated with BC, as well. 
Interestingly, women who had never smoked are the more susceptible1,6. 
Following smokers, occupational exposure to carcinogenic agents is viewed as 
the second most important risk factor for BC. BC-associated carcinogens described in 
literature include aromatic amines, polycyclic aromatic hydrocarbons and chlorinated 
hydrocarbons. Industrial areas, such as processing paint, dye, metal and petroleum 
products, had been associated with BC cases. Other jobs that might increase the risk of 
BC include hairdressers and barbers, painters and coke-production workers1,4,6,8. 
Although diet might also influence bladder carcinogenesis, no consistent 
association between the intake of a specific nutrient or micronutrient and BC has 
emerged so far1. Previous studies associated the intake of fruits and vegetables as a 
protective effect against BC9,10. Other lifestyle factors have been investigated, like the 
consumption of coffee, tea or alcohol, but no meaningfully association has been 
reported11,12. In relation to fluid consumption, the high intake of tap water has been 
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positively associated with BC, probably due to an exposure to arsenic and by products of 
disinfection13. 
Urinary tract diseases can play an important role in the development of BC, 
particularly in developed countries. In these areas of the world, there is a strong 
association between urinary schistosomiasis, caused by trematode Schistosoma 
haematobium, and BC. Other infections in urinary tract can lead to a chronic irritation of 
the bladder epithelium, and thereby increase the risk of BC4–6. 
 
Genetic susceptibility 
 
Familial bladder cancer is considered a rare phenomenon comparing with other 
types of tumor. However, some genetic factors had been established for BC 
carcinogenesis. Polymorphisms in genes coding for enzymes involved in the metabolism 
of urothelial carcinogens highly contribute to susceptibility to BC8. 
The enzyme N-acetyltransferase 2 (NAT2) is involved in detoxification of bladder 
carcinogens, such as aromatic amines and has long been known to be polymorphic. 
Some individuals present an enzyme variant associated with slow metabolization of 
carcinogens. Several point mutations in NAT2 gene associated with the slow acetylator 
phenotype have been identified. Individuals with this polymorphism have 40% higher 
risk of developing BC than individuals with the normal enzymatic variant. The increased 
risk of developing BC seemed to be stronger in cigarette smokers3,4,6,8.  
The Glutathione-S-transferase Mu 1 (GSTM1) belongs to a large family of 
enzymes involved in the detoxification of aromatic amines, a group of bladder 
carcinogens. About 50% of people have an inherited deletion in both copies of GSTM1 
gene, responsible for loss of the enzymatic activity. This polymorphism has been 
associated with higher risk for BC in several studies, although it has no interaction with 
smoking profile3,4,6,8. 
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Sulfotransferases (SULT) and cytochrome P450 enzymes are also involved in the 
metabolism of aromatic amines but the relation between gene mutations and BC 
development is not fully established yet6.  
 
1.1.3 Urothelial carcinogenesis 
 
Bladder cancer is a morphologic highly heterogeneous disease. Approximately 
90% of bladder malignant tumors are transitional cell carcinomas (TCC), which arise 
from transitional cells in the bladder urothelium. Other forms of BC include primary 
squamous cell carcinoma, adenocarcinoma, sarcomatoid carcinoma and small cell 
carcinoma14. 
 Although non-urothelium variants of BC are rare, they are at higher stages and 
grades at presentation and are associated with poor prognosis outcomes, being low 
sensitive to current therapies14. 
Clinically, bladder TCC are divided into superficial and invasive urothelial 
carcinomas. Superficial carcinomas, also called non-muscle-invasive bladder cancers, are 
confined to mucosa or submucosa layers of the bladder. In contrast, invasive carcinomas 
are defined as tumor that reached muscular layers of the bladder wall, through lamina 
propria invasion15,16. 
Superficial bladder carcinomas include papillary tumors and carcinoma in situ 
(CIS) limited to mucosal layer as well as tumors that invade sub-epithelial connective 
tissue, defined in Tumor-Node-Metastasis (TNM) classification as Ta, Tis and T1, 
respectively. On the other hand, the same classification divides muscle-invasive 
carcinomas by grade in T2, T3 and T4, according with the depth of invasion16–18.  
The superficial and invasive tumors are represented in Figure 1. 
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FIGURE 1.1 GRADES OF BLADDER CANCER. 
Bladder carcinoma is a heterogeneous disease that is divided into 7 sub-types, accordingly with TNM 
classification. Low grade tumors correspond to superficial or non-muscle invasive carcinomas, while 
invasive carcinomas represent tumors in higher grades. (Adapted from Hurst et. al., 2015) 
 
 
 
The majority of the BC cases corresponds to papillary lesions as a result of a 
hyperplasia in normal epithelium. Some papillary tumors present a dysplastic 
phenotype, which corresponds to an early stage of progressive alterations between 
normal epithelium and urothelial CIS. The transition of normal urothelium cells to 
dysplastic cells is usually subtle. The majority of cellular alterationsare comprised 
between basal and intermediate cell layers. Dysplastic cells frequently show genetic 
alterations, such as in p53 gene. Only approximately 15% of papillary tumors evolve into 
a higher stage, an invasive TCC. The reason why some TCC cases become invasive is 
currently unknown19. 
In contrast to low-grade papillary tumors, CIS presents genetic instability caused 
by alterations in tumor suppressor genes expression, including TP53, RB and PTEN. 
These mutations lead to a genetic instability and an anti-apoptotic phenotype, causing 
alterations in physiological functions and accumulation of genetic mutations. The 
majority of invasive BCs occur in patients without prior history of papillary tumors19,20. 
CIS evolves to invasive TCC in 60-80% of the cases if left untreated, being the most 
clearly defined precursor of bladder cancer20. The mechanism of tumor progression 
described is illustrated in figure 1.2. 
Introduction 
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The risk of tumor recurrence or progression depends on several histopathological 
factors, such as grade, tumor size, depth of invasion, multiplicity, presence or absence of 
lymph or vascular invasion and presence or absence of CIS16,18. 
Because superficial tumors, by definition, tend to be limited to the basement 
membrane without access to the bloodstream, these tumors have a tendency to be 
smaller and remain localized. In contrast, muscle-invasive tumors represent larger and 
more aggressive malignancies with the capacity to invade adjacent tissues or other 
organs of the body. The last phenomenon occurs due to the presence of lymph and 
blood vessels in muscular layers and is called metastization15–18. 
Since superficial carcinomas correspond to a large spectrum of malignancies, 
their prognosis is also very variable. Low-grade papillary tumors have a low progression 
rate despites their high risk of recurrence, while high-grade TCC lesions, especially T1 
cancers, have a high potential to recur and progress, becoming invasive17. 
Muscle-invasive tumors have a worse prognosis than superficial tumors, being 
intrinsically related with poor outcomes. Within invasive tumors, the probability of 
develop a metastasis disease increases progressively with the stage, while 5-years 
survival rate decreases with the tumor aggressiveness16,18. 
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FIGURE 1.2 BLADDER CARCINOGENESIS. 
Bladder tumors follow papillary pathway, leading to superficial tumors in most of the cases. Only 15% of 
tumors that follow the papillary pathway will progress to invasive tumors. Non-papillary pathway occurs in 
a small percentage of cases and associated with more aggressive tumors. (Adapted from Czerniak et al., 
2014) 
 
 
 
1.1.4 Diagnosis and Treatment 
 
Currently, the diagnosis of BC is based on imaging techniques, such as magnetic 
resonance imaging (MRI), and an endoscopy test followed by histological examination of 
the material obtained by biopsy. Unfortunately, these diagnosis tools do not detect all 
BC cases4. Over the past decades, the scientific community has been able to identify 
biomarkers to enhance the detection of BC. These group of biomarkers have higher 
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sensitivity and include cytokeratines, hyaluronic acid or antiapoptotic proteins, like 
survivin21. 
The choice of an appropriate treatment for BC is essential for overall survival given 
the high tendency to progress and metastasize in the absence of a correct management. 
The first procedure after the diagnosis of BC is the transurethral resection (TUR) of all 
the visible lesions in the bladder wall14. 
For low-grade non-invasive tumors, the surgical resection is considered sufficient, 
however most of them will recur within a 5-years period, frequently without tissue 
invasion. These cases rarely result in death of the patients. Intravesical chemotherapy or 
immunotherapy are performed to reduce the risk of progression or recurrence4,14,22. 
Although a variety of intravesical therapies are used to treat BC, one of the 
standard procedures is Bacilus Calmette-Guérin (BCG) therapy. Briefly, administrated 
live BCG interacts with urothelial cells and is internalized by cancer cells through 
macropinocytosis. Then, BCG internalization lead to an overexpression of MHC-II and 
ICAM-I molecules, which facilitate the antigen presentation to immune cells, and a 
secretion of cytokines, such as IL-6 and IL-8, that recruit immune cells to the site. 
Subsequently, infiltrating immune cells exert their cytotoxic effect against tumor cells by 
several mechanisms23. 
Interestingly, natural killer (NK) cells, among other immune cells, are capable to 
reach bladder tissue after BCG therapy. The cytotoxicity of BCG-specific NK cells, which 
occurs essentially by perforin mechanism (explained in detail in NK section), is 
augmented by IL-12 and interferon (IFN)-γ and inhibited by IL-10. BCG therapy is used in 
high-risk superficial tumors upon TUR and it is associated with decreased risk of 
recurrence and progression to an invasive stage23. 
In an attempt to decrease the risk of recurrence and progression, the intravesical 
therapy with chemotherapeutic drugs is widely used in clinical practice.  Mitomycin 
(MMC), doxorubicin (DOX) and epirubicin are the most common drugs used, which are 
administrated immediately after resection14,24. 
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In most aggressive cases, the standard care involves the radical cystectomy. Due to 
the high risk of recurrence, chemotherapy has been recommended as an adjuvant 
therapy to occult micro metastases. Several combinations of chemotherapeutic agents 
have been tested in clinical trials, presenting similar effects on patient’s survival. The 
group of chemotherapeutics includes cisplatin, doxorubicin, methotrexate and 
vinblastine14. 
Cisplatin-based chemotherapy has remained as the first-line treatment for BC for 
decades due to its lower cytotoxic effect comparing with other drugs. As a result of it, 
little progress has been made in developing novel agents for BC treatment and medium 
survival for patients with high-grade BC has not change significantly, remained at about 
12 months14. 
Currently available therapies for BC consistently fail in eradicating permanently the 
tumor and the relapse often occurs. Chemotherapeutic drugs used in cancer usually 
induce tumor shrink but it grows back after some time18. This phenomenon may be 
explained by the presence of a small population of cells with drug-resistant phenotype 
and ability to induce tumor growth, named cancer stem cells (CSCs)25,26. Therefore, it has 
been suggested that CSCs-targeted therapies could provide a long-term disease-free 
survival when associated with non-CSCs therapies27.  
 
1.2 Cancer stem cells 
 
 
1.2.1 Definition and Discovery 
 
Normal stem cells are defined as undifferentiated cells capable to generate 
mature cells through a differentiation process. Essentially all tissues in the human body 
present a pool of adult stem cells that possess the ability to self-renew and generate an 
organ-specific cell following a hierarchical model28,29. 
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It has been proposed a cancer hierarchy model for carcinogenesis, which 
postulates that a tumor is organized like a normal tissue with a subset of stem cells 
responsible for the generation of identical daughter stem cells as well as cells that 
undergo differentiation to become specialized tissue cells. In this model, CSCs are lying 
in the apex of the tumor hierarchy and they are responsible for sustaining tumor 
growth26. 
The CSCs frequency is highly variable among tumors with a relative low 
frequency in solid tumors. The CSCs proportion also varies widely in tumors of the same 
type. Recent evidences indicate that advanced tumors might have a higher CSCs 
fraction27,30. 
CSCs were first identified in 1994 in acute myeloid leukemia (AML).  This initial 
report demonstrated that only a small population of cells, characterized as CD34+CD38- 
cells, was able to reproduce a heterogeneous tumor when transplanted to a severe 
combined immunodeficiency disease (SCID) immunodeficient mice. The formed tumor 
presented cells in various stages of differentiation and contained multiple mature blood 
cell types. Therefore, the authors demonstrated the existence of a subset of cells with 
the ability of self-renewal and extensive proliferation31. 
Since this discovery, cells with stemness features were found in several solid 
tumors, such as breast, brain or colon cancer32–34.It has been used several terms to 
describe CSCs, namely cancer initiating or cancer propagating cells. 
 
1.2.2 Cancer Stem Cell hypothesis 
 
The majority of the tumors presents a functionally and phenotypically 
heterogeneity among cancer cells. Two models have been proposed two explain the cell 
heterogeneity within the tumor: the stochastic/clonal evolution model and the CSCs 
model, which are illustrated in Figure 1.335,36. 
The stochastic model is a nonhierarchical model, which assumes that any cell 
within the tumor has the same tumorigenic potential. This model postulates that the 
 12 
 
tumor heterogeneity is caused by genetic and epigenetic changes leading to a selection 
process. Thus, the appearance of advantageous genetic/epigenetic changes tends to 
cause more aggressive tumors over the time, whereas disadvantageous 
genetic/epigenetic alterations contribute to the loss of tumorigenic potential. The 
stochastic model predicts that the heterogeneity could lead to differences in therapy 
response37–39. 
The CSC model postulates that only a small group of cancer cells can proliferate 
extensively given rise to non-tumorigenic tumor cells, which compose the bulk of the 
cells in the tumor. Unlike CSCs, non-tumorigenic tumor cells have little capacity to 
contribute to the disease progression40.  In this model, the differentiation of CSCs can 
provide a mechanism of generation phenotypic and functional heterogeneity. Cancers 
that follow the CSC model are also subject to clonal evolution as well as environmental 
pressures35,36,38. 
Several data support the CSCs model in several types of cancer, such as leukemia, 
breast or brain31,32,34. In each case, the ability to propagate the disease upon 
transplantation into an immunocompromised NOD/SCID mice appeared to be restricted 
to a small population of tumor cells. These studies also prove that tumorigenic and non-
tumorigenic cancer cells have a distinct immunophenotype41. 
Although recent studies in many types of cancer strong suggest that these tumors 
follow the CSC model, it seems that this model cannot be applied to all types of 
cancer35,38. 
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FIGURE 1.3 CLONAL EVOLUTION MODEL AND THE CANCER STEM CELLS MODEL. 
Clonal evolution model states that tumor heterogeneity is caused by the occurrence of series of genetic 
mutations that confer a selective growth advantage, while CSCs model propose the existence of a pool of 
CSCs in the ability of generate heterogeneity through a differentiation process. (Adapted from Lindeman 
et al., 2012) 
 
1.2.3 Cancer Stem Cells biology 
 
Despites the name, a CSC is not necessarily derived from a normal tissue stem cell 
that undergo trough mutations giving rise to a malignant clone. CSC can arise from 
differentiated cells as a result of mutations that activate self-renewal mechanisms, thus 
acquiring the properties of a stem cell42. 
The location of CSCs within the tumor is not fully known. Like adult stem cells, 
CSCs may exist in a physiological limited and specialized microenvironment, named CSC 
niche. The CSCs niche has the functions of maintain the stem cell pool, varying in nature 
and location with the tumor type. The existence of a CSCs niche has been associated 
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with CSCs quiescent state since the microenvironment would produce molecules with 
proliferation and growth inhibitory functions.  Several data reinforce the idea that the 
niche may be important for maintaining the asymmetric division and consequently the 
self-renew property of CSCs but there is no agreement if CSCs require a specific niche or 
they are capable of survive in normal stem cell niche43,44. 
Over the last years, several groups have been trying to identify CSCs markers 
among diverse types of tumor in order to distinguish CSCs from cancer cells with more 
limited proliferative potential. Due to the highly inter- and intratumoral heterogeneity, 
the identification of CSCs markers has been difficult. Fortunately, the rapid development 
of the CSCs field combined with genome screening techniques has allowed the 
identification of new CSC markers in a wide range of tumors45,46.  
Each type of cancer has distinct combination of surface markers that demark the 
CSCs pool. CD44, CD24, CD133, EpCAM and ALDH1 have been commonly used as CSC 
markers in many types of cancer however they are not considered universal markers. 
Nonetheless, these markers are not exclusive for CSCs in any tumor26,45,46.  
The existence of a CSCs subset has been extensively studied in breast, prostate, 
glioblastoma and lung cancer among other malignancies. The range of markers used to 
identify CSCs in several solid tumors are described in table 1. 
 
TABLE 1.1Phenotype of cancer stem cells among several malignances. 
Type of tumor CSCs phenotype Reference 
Breast CD44+CD24-/lowCD133+ 32,47 
Prostate CD44+CD133+ 48 
Lung CD133+ 49 
Glioblastoma CD133+CD15+ 50 
Melanoma CD20+CD271+ 51 
Pancreas CD44+CD24+ESA+ 52 
Liver CD133+ 53 
ESA: epithelial specific antigen 
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Other markers have been used to isolate CSCs from the remainder cell population, 
particularly pluripotency-related genes such as Oct4, Sox2, Nanog or Nestin that 
cooperate to maintain the self-renewal and pluripotency properties of stem cells54. 
CSCs can be isolated by other assays than flow cytometryaccording to CSC-specific 
surface markers. These functional assays include the sphere-forming assay, the 
assessment of aldehyde dehydrogenase (ALDH) activity and evaluation of cell 
tumorigenicity in SCID immunodeficient mice55. 
The sphere-forming assay is one of the most used techniques to isolate CSCs from 
progeny, based on the capacity of CSCs to grow in non-adherent conditions, forming 
colonies from a single cell. To perform this assay, a low number of tumor cells (to assure 
that each colony derived from a single cell) are cultured in serum-free medium, usually 
using soft agar or matrigel as support. During culture periods, some molecular factors 
are added to promote the maintenance of the CSCs-like phenotype, such as EGF, bFGF 
or B2755–57. 
Although the mechanism underlying clonal spheres formation is poorly 
understood, this technique pretends to generate populations of tumor cells with the 
capacity to self-renewal and grow in suspension under serum-free conditions. This 
procedure might be repeated to produce a more purified population of CSCs55–57. 
The measurement of ALDH activity is another technique that allows the isolation 
of CSCs. ALDH is an enzyme responsible of detoxification of aldehydes, leading to 
formation of retinoic acid, which confers resistance to some chemotherapeutic agents 
like cyclophosphamide. High levels of ALDH activity has been associated with low 
survival rates and chemo resistance and identified tumor cells with stem cells features in 
some tumors, like breast or colon. Although ALDH family consist in a group of enzymes, 
the well-studied member is ALDH1A155,58,59. 
To isolate CSCs using ALDH activity, tumor cells are sorted in a flow cytometer 
accordingly with their ALDH activity into ALDHbright and ALDHlow cells. The ALDHbright cells 
usually exhibit CSCs-like features55,58,59. 
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Ultimately, the main principle of CSCs is their capacity to form a heterogeneous 
tumor when a small group of cells is transplanted to a SCID immunocompromised mice, 
resembling the original tumor. Theoretically, a single cell is able to generate a whole 
tumor, however none of the previous studies achieved that purification state60,61. 
Previous study reported that non-CSC populations also form heterogeneous 
tumors SCID immunocompromised mice, but in a much lower frequency and requiring a 
higher cell number. Two models are currently used toevaluate the tumorigenic potential 
of CSCs, namelythe subcutaneous and the orthotopic models. In subcutaneous 
xenograft, tumor cells are injected subcutaneously and the tumor grows in a different 
organ of origin, while in orthotopic model cells are directly delivered to the normal 
organ niche60,61. 
 
1.2.4 Drug resistance and therapeutic implications 
 
Even though current cancer therapies, such as chemotherapy and radiotherapy, 
are responsible for killing the majority of cells in the tumor, frequently the tumor 
relapses. This might be explained by the presence of a CSC pool within the tumor mass, 
which are less sensitive to these therapies. Thus, CSCs remain viable after the treatment 
and have the ability to re-establish the tumor35,62. 
Anticancer therapies mostly fail to eradicate the CSCs pool instead favor their 
expansion and/or selection of resistant clones. Thus, the successful elimination of a 
cancer requires an anticancer therapy focused in differentiated cancer cells and 
potential CSCs35,62. 
It has been suggested that CSCs are resistant to diverse therapy approaches in the 
same way that normal stem cells are protected against injuries. The protection 
mechanisms include quiescence status, expression of ATP-Binding Cassette (ABC) 
transporters, high expression of antiapoptotic proteins and enhanced DNA-damage 
repair mechanisms, previously described25,63.  
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One particularly characteristic of CSCs is their ability to enter in a quiescent stage, 
dividing infrequently. Quiescence might be a crucial mechanism to drug resistance since 
chemotherapeutic drugs act mainly in highly proliferating cells. Further, the dormancy 
state might explain the tumor recurrence or metastasis after long lag periods64. 
Another mechanism of CSCs drug resistance is their augmented expression of ABC 
transporters members, such as P-glycoprotein (P-gp), Breast Cancer Resistance Protein 
(BCRP) and Multidrug Resistance-associated proteins (MRPs). These receptors are 
responsible for the drug efflux in an ATP-dependent mechanism. Thus, 
chemotherapeutic drugs that are substrates of ABC transporters do not remain in the 
interior of cells long enough to induce apoptosis63. 
The escape from induction of apoptosis has been considered one of the hallmarks 
of CSCs, representing a key mechanism against oncogenic events. CSCs present 
compensatory mechanisms to escape from apoptosis fate otherwise they were not 
capable of survive and self-renew. The apoptosis escape could be achieved specially by 
increasing levels of anti-apoptotic proteins or decreasing the quantity of pro-apoptotic 
members65. 
Further, CSCs have a higher activation and expression of genes and proteins with 
DNA-repair functions than non-CSCs. Thus, CSCs use more genetic repair mechanisms, 
allowing the maintenance of their functional abilities66. 
It has been proposed that cancer therapies currently employed might cause a 
positive selection of resistant cancer cells and dissemination of CSCs from their niche. 
When subjected to a new set of microenvironmental selection pressures, CSCs acquire a 
different phenotype, leading to CSCs heterogeneity. CSCs heterogeneity was recognized 
in many types of cancer, including BC, using karyotyping approach and suggested as a 
cause to differences in patients therapeutic responses40. 
Despite the true clinical relevance of the CSCs population is yet to be revealed, it 
seems that therapies directed against CSCs might be essential to long-term disease-free 
survival28. The tumor progression after current therapies are illustrated in figure 1.3. 
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FIGURE 1.4 TUMOR PROGRESSION AFTER CHEMOTHERAPY. 
Currently therapies do not affect the CSC pool, which re-establish the tumor. In contrast, therapies 
directed to CSCs promotes their elimination prevent tumor grow and reappearance. (Adapted 
fromWeissmanet al., 2001) 
 
 
1.2.5 Bladder Cancer Stem Cells 
 
The human urothelium is constantly renewing itself during normal homeostasis. 
This ability is achieved by the presence of basal stem cells with a high capacity for cell 
division. Urothelium stem cells are protected from differentiation, loss of self-renewal 
capacity and apoptosis by a specific anatomical and functional microenvironment, called 
niche29,67. 
Although their origin remains unknown, it has been described a tumorigenic basal 
cell population in the interface between tumor and stoma, that resemble benign 
urothelial stem cells. This population might represent bladder CSCs68,69. 
Like in other types of cancer, bladder CSCs can give rise to a heterogenic tumor 
population by differentiating in down-stream tumor cells67. 
Several studies demonstrate that a cell population identified as bladder CSCs is 
more resistant to cisplatin-based treatments, which are the most commonly used drugs 
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to advanced BC.  This phenomenon might be due to CSCs characteristics described 
above70. 
In last years, the epithelial to mesenchymal transition (EMT) has been associated 
with stemness and CSCs origin in epithelial tumors, playing a role in cancer progression 
and metastasis3. Several recent studies propose that the generation of bladder CSCs 
occurs during tumorigenesis following EMT, through a cell selection mechanism71,72. 
Although the bladder CSC molecular profile is not fully characterized yet, some 
biomarkers have been identified in cancer stem-like cells. CD44 is one of the most 
prominent molecules implicated in cell adhesion and used for bladder CSCs isolation. 
The tumorigenic potential of   CD44+ tumor cell is 10-200 times greater than that of 
CD44- cells73. Several studies demonstrate that intracellular cytokeratin 5 (CK5) is usually 
co-localized with CD44 in tumor cells. In contrast, in immunofluorescence assays CD44- 
cells are often co-localized with CK20 molecule, which is the differentiated molecule of 
CK574,75. 
The ALDH1A1, previously described, has been used to isolate CSCs in BC due to its 
higher expression in bladder cancer stem-like cells. A recent study demonstrates that 
bladder ALDH1A1+ cells has 100-fold greater potential of tumor formation than bladder 
ALDH1A1- cells. Interestingly, ALDH1A1+ cells appear to be enriched in CD44+ tumor cell 
with more primitive CSC features76 
 
1.3 Natural Killer cells 
 
 
1.3.1 Definition, Origin and Types 
 
Natural Killer (NK) cells are a subpopulation of innate lymphoid cells (ILCs) with 
cytotoxic potential. NK cells represent approximately 15% of all lymphocyte in 
bloodstream and have a crucial role in the innate immune system, which is responsible 
for the rapid response and protection against host injuries77. 
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NK cells are developed in bone marrow from common lymphoid progenitor cells. 
After development, these cells distribute throughout tissues, namely bone marrow, 
spleen, lymph nodes and peripheral blood77. 
The human NK cells usually are characterized phenotypically as CD56+CD3-. These 
cells can be divided in two subsets as CD56dim and CD56bright based on the relative 
expression of the CD56 marker. CD56dim NK cells comprise the majority of circulating 
cells, whereas CD56bright set represent only 5-15% of total NK cells, being mainly localized 
in lymph nodes77,78. 
CD56dim NK cells are highly cytotoxic cells upon interacting with target cells but 
have a lower cytokine production potential, when compared with CD56brigh NK cells. In 
contrast, the CD56brigh subpopulation exhibits predominantly immune regulation 
properties by producing high amounts of cytokines, such as interferon-γ (IFNγ) in 
response to stimulation by several interleukins like IL-12 or IL-1578. 
 
1.3.2 Recognition and killing pathways 
 
Natural killer cells have the capability to recognize stressed cells, such as tumor 
cells or virus-infected cells from normal cells in the absence of pre-immunization or 
stimulation. NK cells have a large group of receptors, which enable them to recognize 
altered cells as targets. The group of NK receptors consists of activating, inhibitory, 
adhesion molecules and cytokine receptors, as listed in table 1.2. The combination of all 
signals determines whether an NK cell becomes activated or not79. 
Inhibitory receptors prevent the activation of NK cells and, consequently, their 
action against cells. The inhibition of the lytic process is due to the expression of one or 
more immunoreceptor tyrosine-based inhibition motifs (ITIM), which upon activation 
recruits SHP1, SHP2 and SHIP phosphatases to prevent activation cellular signaling 
cascades80.  
In contrast, activating receptors are associated with immunoreceptor tyrosine-
based activation motifs (ITAM), which recruit Syk upon phosphorylation. Consequently, 
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Sky leads to activation of cellular signaling cascades responsible for degranulation and 
transcription of chemokines and cytokines.  Moreover, NK cells exhibit also a group of 
co-stimulatory receptors. Although these molecules have no capacity to trigger NK cells 
activation by itself, they provide further stimulation. The group of co-stimulatory 
receptors include DMAN-I and NKR-P180. 
The cell adhesion molecules (CAM) are receptors on NK cells surface responsible 
for the interaction with accessory and target cells, being essential players to an effective 
NK cells response81. 
NK cells also exhibit a range of cytokine receptors on their membrane that interact 
with cytokines released by neighbor immune cells, especially dendritic cells. Cytokines 
influence the cytotoxic activity and NK cells82. 
  
TABLE 1.2List of the most import natural killer cells receptors organized by function 
Inhibitory receptors Activating receptors Adhesion receptors Cytokines receptors 
Ly49A 
Ly49C 
KIR2DL1 
KIR2DL2 
NKG2A 
LIR 
KLRG1 
NKG2C 
NKG2D 
NKp30 
NKp44 
NKp46 
DMAN-I 
NKR-P1 
LFA-1 
CD54 
CD58 
NKH-1 
IL-2/15r 
IL-12R 
IL-18R 
IL-21R 
IFNAR 
 
 
The NK cell recognition of a stressed cell is a complex mechanism, mainly 
explained trough two different models: missing-self and stress-induced self 
recognition79,83. 
The major histocompatibility complex-I (MHC-I) is a group of glycoproteins 
expressed by nearly every cell of the body with the function of display cell antigens. 
Every NK cell expresses inhibitory receptors that recognize MHC-I and protects normal 
cells from NK-mediated killing. In cancer, the expression of MHC-I is often reduced or 
even lost, allowing NK activation and action upon these cells (missing-self model)79,83. 
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Besides the inhibitory receptors that identify self, NK cells also have activating 
receptors on their membrane. These activating receptors are able to detect molecules 
that in a steady-state condition would be barely detectable. The upregulation of 
activating receptors ligands is usually associated with various forms of stress, including 
cancer (stress-induced self model)79,83. 
Therefore, the recognition of a tumor cell by a NK cell is a tightly regulated 
process, involving the integration of both positive and negative signals. Whether NK cells 
receive more positive signals, delivered by activating receptors, than negative signals, 
from inhibitory receptors, they become activated, resulting in a target-cell killing. NK 
cells can also be activated by various kinds of cytokines79. 
 
 
FIGURE 1.5Recognition mechanisms of NK cells. 
Tumor cells alterations deregulates the expression of activating and inhibitory receptors, allowing the 
recognition by NK cells and consequently their activation. The recognition occurs when tumor cells loose 
expression of inhibitory ligands, like MHC-I, or due to the upregulation of stress-induced ligands. (Adapted 
from Brossay et al., 2012) 
 
After recognition, NK cells kill directly target cells mainly through by several 
mechanisms, namely the perforin/granzyme system, IFNγ-mediated pathway and the 
death receptors-mediated apoptosis83. 
One way of killing target cells is by releasing cytoplasmic granules, containing 
perforin and granzymes, by exocytosis. Granzymes enter in target cells through pores in 
plasma membrane formed by perforin and then induce cell death in a caspase-
dependent or independent manner.  Granzyme-A activates caspase-independent cell 
death via single stranded DNA damage, while Granzyme-B cleaves caspase-3 resulting in 
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DNA fragmentation, degradation of cytoplasmatic and nuclear proteins. Both molecules 
lead to innumerous biochemical alterations, such as DNA fragmentation, proteins 
cleavage and expression of ligands for phagocytic cells receptors. This killing pathway is 
considered the main mechanism used by NK cells to eliminate target cells84,85. 
 NK cells can kill target cells by promoting the secretion of various effector 
molecules, such as IFNγ. The production of IFNγ by mature NK cells is involved in the 
suppression of pathogens as well as in antitumor functions, like inhibiting angiogenesis 
and stimulating adaptive immunity. A recent study demonstrate that IFNγ contributes to 
control the spread of the tumor85.  
Another mechanism of NK cell-mediated killing is through death receptors (DRs), a 
large group of cell membrane proteins of tumor-necrosis factor (TNF) family86,87. Since 
DR-mediated apoptosis is the main NK killing pathway studied in this work, the DRs are 
described more extensively below. 
Lastly, NK cells are also able of destroy tumor cells by antibody-dependent cellular 
cytotoxicity (ADCC). In this mechanism, CD16 on NK cells membrane binds to an antigen-
associated antibody on target cells surface and, causing NK cells activation and resulting 
in lysis of antibody coated cells. Although this mechanism was observed in in vitro 
models, an effect in anti-tumor response in human remains to be show88. 
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FIGURE 1.6 NATURAL KILLER CELLS EFFECTOR FUNCTIONS. 
Upon activation, NK cells exert their cytotoxic action through several mechanisms, such as release of 
granules containing perforin, engagement with death receptors on target cells and also the release of 
effector molecules like IFN-γ. (Adapted from Yagita et al., 2002) 
 
During tumor progression, cancer cells promote some mechanisms to escape from 
NK cell recognition and attack. These defense mechanisms include a downregulation of 
molecules that promote the NK-mediated killing, like co-stimulatory ligands or ligands 
for activating receptors, or an upregulation of inhibitory signals, such as MHC I. 
Moreover, tumor cells can protect themselves from an immune response by secreting 
immunosuppressive molecules, including IL-10 and TGF-β, and resisting Fas- or perforin-
mediated apoptosis89. 
 
1.3.3 Death receptors 
 
Death receptors belong to the tumor necrosis factor (TNF) superfamily, which 
includes more than 20 proteins with a wide range of biological functions, including cell 
death regulation and immune regulation87. 
The best recognized death receptors include TNF-R1, Fas (also called CD95 or 
APO-1) and DR5 (or TRAIL-R2). These receptors are expressed in a broad range of cells, 
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including cancer cells, and become activated upon binding to their ligands, expressed 
constitutively in immune cells, like NK cells. The ligands on NK cells which binds to TNF-
R1, Fas and DR5 on tumor cells are TNFα, Fas ligand and TRAIL, respectively87,90. 
The activation of death receptors triggers the apoptotic cellular process. 
Apoptosis is considered a controlled cellular mechanism capable of eliminate altered 
cells and characterized by morphological and biochemical alterations, such as DNA 
fragmentation, membraneblebbing and cell shrinkage87. 
The apoptosis machinery can be activated by two main pathways: the intrinsic 
pathway, mainly engaged by chemotherapeutic agents, and the extrinsic pathway, 
associated with death receptors. Unlike intrinsic pathway, the extrinsic pathway is 
independent of mitochondria and leads to apoptosis in a p53-independent manner. 
Although different molecules play a role in both pathways, there is a crosstalk at 
multiple levels86. 
The ligand-receptor binding induce the formation of a macromolecular complex, 
named DISC, which recruits procaspase-8, an initiator caspase. In death-inducing 
signaling complex (DISC), procaspase-8 is converted into caspase-8, its active form, 
which is released into the cytosol where directly cleaves effector caspases-3 and -7, and 
consequently leads to apoptosis. In the other hand, activated caspase-8 cleaves BID, a 
BH3 domain-containing proapoptotic Bcl2 family member, which in turns interacts with 
BAX and BAK proteins to release mitochondrial cytochrome c. Once cytochrome c is 
released from the mitochondrial compartment, it binds to APAF-1, forming the 
apoptosome. This complex induce activation of effector caspases -3 and -7 mediated by 
caspase-9 action86. 
Interestingly, death receptors expression may vary between cell types and is 
often downregulated or absent in resistant tumor cells. This phenomenon has been 
associated with the tumor immune escape90. 
Several studies have demonstrated that a death-receptor-based therapy exert a 
robust anticancer therapy. In this direction, some death receptors agonists (dulanermin, 
mapatumuab or lexatumumab) have been followed in clinical trials for multiple cancer 
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types, such as multiple myeloma, breast, leukemia or BC in single treatments or in 
combination with chemotherapeutic drugs91. 
Some studies with DR5 are already in phase II and results are promising in terms 
of safety and efficacy. In the other hand, administration of soluble Fas ligand was 
reported as highly cytotoxic due to its systemic consequences87,91. 
Unfortunately, TNF-α has been used in several clinical trials in a cancer treatment 
context but the results have been disappointed. Besides its severe toxic effects, several 
data indicate that TNF-α has a low efficacy rate. Besides this disappointment, the idea of 
target death receptors to trigger apoptosis in tumor cells remains as attractive 
antitumor approach, especially because occurs independent of p53 tumor suppressor 
gene, which is deleted or inactivated in many tumors. Thus, death receptor approach is 
focused on DR5 and Fas receptors86,91. 
So far, there is no report of ongoing clinical trial that explores the death 
receptors potential in NK-mediated killing, however in vitro and animal model 
experiments in leukemia, prostate and multiple myeloma demonstrated that an 
upregulation of death receptors on tumor cells increases the cytolitic potential of NK 
cells. Thus, the increase of death receptors in tumor cells comes up as an attractive 
approach to sensitize tumor cells to NK-based immunotherapy86,91. 
Recently, several data indicate that doxorubicin, a chemotherapeutic drug, and 
bortezomib (BTZ), also called PS-341, a proteasome inhibitor, induce Fas and DR5 
expression in tumor cells, which could lead to sensitization of tumor cells to NK cell-
mediated killing92–97. 
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FIGURE 1.7DEATH RECEPTOR SIGNALING PATHWAY 
The pro-apoptotic receptors of NK cells bind to death receptors on tumor cells. ligand binding induce the 
activation of extrinsic apoptosis signaling cascade by recruitment of Fas-associated death domain (FADD) 
and initiator procaspase-8 and procaspase-10, forming DISC. This complex triggers activation of caspase-3 
and -7, the effector caspases. Caspase-8 can also cleave BH3-interacting domain (BID), which promotes 
mitochondrial release of cytochrome c and, consequently formation of apoptosome and activation of 
caspase-3 and -7. (Adapted from Krammer et al., 2002) 
 
1.3.4 Immunotherapy 
 
Although immune surveillance of tumor has been a controversial subject for 
decades, there is evidence that immunosuppressed patients have a tendency to develop 
some kinds of malignancies89. Furthermore, some NK abnormalities have been observed, 
such as lower proliferation rates, reduced cell cytotoxicity, overexpression of inhibitory 
receptors and defective cytokine production83. 
 28 
 
Low levels of NK cells in peripheral blood has been associated with higher risk of 
cancer while enhanced levels of NK cells in peripheral blood have a significantly longer 
metastasis-free survival time78,83,98. 
The presence of NK cells within the tumor tissue appears to be a good prognosis 
factor, at least for several types of cancer. Further, some studies have demonstrated 
that NK cells are highly effective at eliminating tumors, especially small tumor grafts and 
metastasizing cells99–101.  
Due to their great potential to recognize and eliminate tumor cells, NK cells appear 
to be one of the most likely effectors for an effective antitumor immune therapy. Thus, 
they have been widely studied in several immunotherapeutic approaches for cancer and 
recently trialed in a clinical context78,98,102. 
The NK cell-based therapies have been most successful in hematopoietic cancer 
but more recently the immunotherapies using NK cells have been more studied in solid 
tumors and metastatic cancers78,83. 
The use of NK cells in an immunotherapy approach has many advantages in a 
clinical context. NK cells are antigen non-specific and do not require a specific donor HLA 
allotype, avoiding rejection risk. These immune cells recognize a broad group of ligands 
that induce a cytolitic response. Thirdly, NK cells can be easily isolated and expanded ex 
vivo, allowing their use in both adoptive and autologous cell therapies78. 
Importantly, some recent studies suggest that NK cells appear to kill CSCs more 
effectively than chemo and radiotherapy, the common therapeutic approaches for 
cancer. Since NK cells are capable of target and eliminate both CSC and non-CSC 
population, NK immunotherapy is theoretically an effective antitumor therapy103,104. 
There are several approaches to NK-based immunotherapy. One of the strategies 
already studied in a clinical trials is the administration of cytokines, which promotes the 
proliferation and activation rates of endogenous NK cells through a direct or indirect 
mechanism. Activated NK cells present a higher cytotoxic potential than non-stimulated 
cells. The group of cytokines used in cancer treatment includes IL-2, IL-12 and IL-15. 
These cytokines bind to specific receptors on NK cells (previously described) and 
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promote an increase in NK cytotoxic potential due to an augment of IFNγ production 
and also NK cell survival78. 
The obtained results from these clinical trials vary accordingly with the kind of 
tumor and cytokines administration conditions. The use of cytokines in cancer therapy 
has two main limitations, namely the toxicity of their systemic administration and 
cytokine-activated NK cells apoptosis83. 
Immunomodulatory drugs, like thalidomide and their analogues used in some 
cancers, such as myeloma, can also activate NK cells by increase IL-2 secretion in T-cells, 
which explain in part the mechanism of these anticancer drugs105. 
Other therapeutic strategies for cancer include the use of exogenous NK cells via 
hematopoietic stem cell transplant (HSCT) or adoptive cell transfer (ACT)78. 
HSCT is most common used in hematological malignancies, being divided 
according to the donor cell source in autologous (the donor and the recipient are the 
same person) and allogeneic (the donor and the recipient are different persons). After 
the HSCT, NK cells are the first lymphocytes to repopulate, being capable of mediate 
graft-vs-tumor, which occurs when graft recognizes the tumor population.  NK cells 
don’t contribute to graft-vs-host disease in contrast to other lymphoid populations, like 
T cells78. 
The administration of autologous NK cells with high doses of IL-2 were tested in 
models of glioma, renal carcinoma or melanoma, but results were disappointing since 
subsequently studies showed similar effect when IL-2 were administrated alone. 
Although both autologous and allogeneic NK cells can be used for ACT, the lack of 
significant results with autologous NK cells led to shift the focus to allogenic cells98. 
  The administration of allogenic NK cells must be associated with intravenous 
injection of activating cytokines, otherwise NK cells undergo apoptosis before of interact 
with the tumor. The group of cytokines that regulates survival, proliferation and function 
of NK cells include IL-2, IL-12, IL-15 and IL-18, resulting in a far greater NK cells activation 
and cytotoxicity that can be achieved in vivo. It has not been reported adverse side 
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effects of NK cell allogenic transfer. The main obstacle of ACT is the low number of NK 
cells in peripheral blood mononuclear cells (PBMCs) and effector cells preparation78,98. 
As already mentioned, the increase in the death receptors levels in tumor cells 
appear to be a possible alternative to currently NK cells immunotherapies. This approach 
has been poorly explored to improve NK cells cytotoxic activity in the presence or 
absence of activating cytokines106. 
It is likely that combinatory therapies, in which NK cells are one of components, 
will become the main therapeutic approach for many types of cancer in the near future. 
The combination of therapies with NK cell therapy can promote synergetic antitumor 
effects102. 
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 The main goal of this work is to investigate the effects of sub-apoptotic concentrations 
of DOX and BTZ in the sensitization of bladder cancer cells (parental cells and corresponding 
CSCs) to NK cells-mediated cytotoxicity through upregulation of death receptors. To achieve this 
goal we propose to: 
 
 Isolate subpopulations of CSCs from two human bladder carcinoma cell lines (UM-
UC3 and HT-1376), using the sphere-forming assay; 
 Perform the characterization of parental bladder cancer cells and CSCs regarding 
expression of death receptors  Fas and DR5; 
 Identify the concentrations of DOX and BTZ that promote the upregulation of the  
two major death receptors Fas and DR5 in bladder cancer cells; 
 Assess the effects of DOX and BTZ in bladder cancer cells susceptibility to NK-
mediated killingthrough death receptor-mediatedapoptosis; 
 Perform the characterization of death receptors expression in specimens of human 
bladder cancer tumors; 
 
 
 
  
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3.1 Bladder carcinoma cell lines 
 
The human UM-UC3 and HT-1376 bladder carcinoma cell lines were purchased 
from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cell lines 
grow in monolayer and were routinely cultured in RPMI 1640 medium (R4130, Sigma-
Aldrich, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Invitrogen Life 
technology), 1% antibiotic/antimicotic containing 100U/mL penicillin, 100μg/mL and 0,2 
μg/mL amphotericin B (Sigma-Aldrich, USA) and 1% L-glutamine (Sigma-Aldrich, USA). 
Cells were maintained at 37oC in a 5% CO2-95% air atmosphere and passaged in sterile 
conditions when reaching 80% of confluence. Cells were discarded after 40 passages. 
 
3.1.1 Cell viability 
 
The viability of cells was assessed before all experiments through the trypan blue 
method. Trypan blue is a stain that confers a distinct blue color to non-viable cells when 
observed at microscope, while viable cells remain unstained. This phenomenon occurs 
due to the fact that non-viable cells do not exhibit an intact and functional membrane to 
prevent the dye uptake. 
To perform this technique, equal volumes of cell suspension and 0,4% trypan 
blue solution (Sigma Chemicals) were mixed and transferred by capillary action into a 
Neubauer hematocytometer (Optic Labor). Then, cells were observed and counted in an 
inverted microscope (Nikon, Eclipse TS 100). Both viable (unstained) cells and non-viable 
(stained) cells were counted in two or more of four corner quadrants. 
Cell viability was calculated using the following expression: 
 
݊ݑܾ݉݁ݎ	݋݂	ݒܾ݈݅ܽ݁	݈݈ܿ݁ݏ = ݈݈ܿ݁	ܽݒ݁ݎܽ݃݁	 × 	10ସ × ݈݀݅ݑݐ݅݋݊	݂ܽܿݐ݋ݎ 
 
Only cellular suspensions with viabilities higher than 90% were used in all 
experiments. 
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3.2 Reagents 
 
The proteasome inhibitor, BTZ, was provided by Cell Signaling Technologies. 
Stock BTZ solution (6,5mM) was prepared in sterile dimethyl sulfoxide (DMSO) and 
stored at -80oC. The stock solution was diluted to 1mM solution in DMSO and stored at -
80oC as well. Aliquots from 1mM solution were stored at -20oC for up to months. The 
1μM solution was prepared from 1mM solution and diluted in Dulbecco’s PBS solution, 
immediately before the use. BTZ solutions were protected from the light at all times. 
Doxorubicin was obtained from DOXO-CELL. Stock solution (3,45Mm) was diluted 
in Dulbecco’s PBS solution and stored at -20oC. Any diluted solution was prepared 
immediately before use. 
Concanamycin A (CMA) was obtained from Santa Cruz Biotechnology. Stock 
solutions (57,7μM) were prepared in sterile DMSO and maintained tightly sealed at -
20oC. The 2 μM solutions were prepared from stock solution, aliquoted, stored at -20oC 
and thawed only once.  
 
 
3.3 Sphere‐forming assay 
 
 The isolation of CSCs from UM-UC3 and HT-1376 cell lines was performed using 
the sphere-forming assay.  For this assay, a cell suspension containing 2x105cell/mL were 
mixed with Matrigel (BD Biosciences). Then, 100μL of the cell/matrigel mixture were 
added to each well in a 12-well plate (Orange Scientific). Cells were incubated for 30m at 
37oC before the addition of 1mL of serum-free DMEM/F12 medium supplemented with 
2μl/mL bFGF (Peprotech), 2μl/mL EGF (Sigma-Aldrich) and 20μl/mL B27 (GIBCO, Life 
technologies). The medium was changed every three days. 
The spheres were collected after 7-9 days of culture by addition of 1mg/ml of 
dispase solution (GIBCO, Invitrogen Corporation) and incubation for 45m-1h at 37oC. 
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After that, the cell aggregates were transferred to a tube and centrifuged at 1500RPM 
for 5m and then incubated with 500μL of accutase solution (Sigma-Aldrich, USA) for cells 
dissociation. After 5m, RPMI medium containing 10%FBS was used to stop the accutase 
reaction and the cell suspension was centrifuged at 1500RPM for 5m. Once centrifuged 
and the supernatant was removed, CSC were prepared to use. 
 
3.4 Cytotoxic assays 
 
 
The cytotoxicity of DOX and BTZ was accessed using the [3-(4, 5-Dimethylthiazol-
2-yl)-2, 5-Diphenyltetrazolium Bromide] (MTT) colorimetric assay. When the cell 
confluence reached 80%, cells were detached using trypsin/EDTA (Sigma-Aldrich), 
counted and seeded in 96-multiwell plates.  
The cell density plated per well was determined accordingly with the period of 
incubation with the drugs and the cell growth rate in order to avoid cells reaching full 
confluence. Briefly, for the 48h incubation assay, cells were plated at a density of 10.000 
cells/well or 12.000 cells/well for UM-UC3 and HT-1376, respectively. In 24h incubation 
assay, cells were seeded at 7500cells/well or 9500 cells/well for UM-UC3 and HT-1376, 
respectively. 
After 24h incubation, to allow cells attachment to the wells, drug solutions or 
fresh RPMI 1640 medium (control) were added to each well at different concentrations, 
in duplicate. The DOX concentrations added to tumor cells vary between 0.01µM and 
0.1 µM (0.01µM, 0.025µM, 0.05µM, 0.075µM and 0.1µM) while the range of BTZ 
concentrations include 5nM, 10nM and 20nM. Plates were incubated for an additional 
24h or 48h in the CO2 incubator.  
After the incubation periods, the culture medium was removed and 50μl of MTT 
solution (Sigma-Aldrich) at 0.05mg/mL was added to each well. Then cells were 
incubated for 4h at 37oC protected from the light. Subsequently, the formazan crystals 
were dissolved in 100μl of 0,04M Isopropanol and the absorbance was measured at 
Material and methods 
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570nm and 620nm in SynergyTM HT multi-detection microplate reader (BioTeck) using 
Gen 1.09 software. 
The signal intensity generated is dependent of the quantity of formazan, the 
product of MTT reaction, which is directly proportional to the number of viable cells 
since only viable cells can reduce MTT to formazan. The cell viability was calculated as 
percentage of the average absorbance of treated cells relative to the absorbance of 
untreated control cells using the following formula: 
 
%	݈݈ܿ݁ݑ݈ܽݎ	ݒܾ݈݅ܽ݅݅ݐݕ = 	 ܣܾݏ	(ݏܽ݉݌݈݁)ܣܾݏ	(ܿ݋݊ݐݎ݋݈) 	× 	100 
 
 
 
3.5 Gene expression analysis 
 
 
3.5.1 RNA extraction 
 
 The RNA extraction is the first step to investigate the gene expression of cell 
lines. The extraction of total RNA was performed using TRIzol reagent (Invitrogen). 
Briefly, 1 ml TRIzol was added to samples in order to promote biological material 
solubilization and protein denaturation. Samples were incubated for approximately 5 
min with constant agitation before the addition of 200µL chloroform. Then, samples 
were centrifuged at 13 000RPM for 10 min at 4oC.  
The centrifugation process promotes the formation of three layers: the lower 
layer constituted by chloroform, an interphase layer containing proteins and lastly an 
aqueous layer with RNA molecules. Thus, aqueous (upper) layer is transferred into 
another tube.  
Then, 200µL isopropanol was added to wash and precipitate RNA present in the 
solution. Subsequently, the sample was centrifuged at 13 000RPM for 10 min at 4oC and 
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the formed pellet was washed with 500µL of ethanol. After removing the main 
supernatant, the pellet was left at room temperature to dry and 100µL solution of H2O 
mQ was added to dissolve the obtained RNA pellet.  
 The concentration and purity of isolated RNA were assessed using a NanoDrop 
ND-1000 spectrophotometer (Thermo Scientific, USA). The ratio of absorbance at 260nm 
and 280nm is used to assess the purity of the RNA preparation. Only samples with 
A260/A280 ratio higher than 1.6 were used in qRT-PCR technique.  
 
 
3.5.2 Complementary DNA synthesis 
  
The RNA was reverse transcribed using NZY First-Stand cDNA Synthesis kit 
(Nzytech), accordingly with the manufacturer’s indications. Briefly, 1µg of RNA was 
mixed with 10µL NZYRT 2X master mix, 2µL NZYRT enzyme mix and H2O mQ until make 
up 20µL.  
 The master mix solution contains dioxylnucleotides (dNTPs) that are used two 
the new strand and MgCl2, which acts as a co-factor of reverse transcriptase action. In 
the other hand, the enzyme mix include reverse transcriptase, enzyme that binds dNTPs 
to single strand of RNA in a complementary-manner, as well as ribonuclease inhibitor to 
protect the degradation of RNA. 
 Samples were incubated at 25°C for 10 min, followed by 50°C for 30 min for 
cDNA synthesis, and then at 85°C for 5 min for reverse transcriptase inactivation, using 
system 9700 thermal cycler (Applied Biosystems).  
 Finally, RNA strand is degraded by adding 1 µL RNase H (E. Coli) and incubated at 
37°C for 20 min, leaving a single stranded cDNA ready for qRT-PCR. Obtained samples 
were diluted 25x and stored at -80oC until use. 
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3.5.3 qRT‐PCR 
 
Quantitative real-time PCR was performed using a Perfecta SYBR Green Fast Mix 
(Grisp®) in a CFX96 real-time PCR detection system (Bio-Rad, Irvine, CA, USA). GAPDH 
and 18S were used as housekeeping genes for normalization.  
The sequences of sense and antisense primers for human FasR, DR5, GAPDH and 
18S are described in table 3.1 and were purchased from NZYTech. Water was used as a 
negative control. BLAST® searches were performed to confirm the total gene specificity 
of the primer sequences. 
To execute the experiment, we mix 2.5µL of cDNA with 10µL of a master mix, 
containing 6.25µL SYBR Green Fast Mix, 3.25 µL H2O mQ and 0.5µL primer mix. Each 
sample was tested in duplicate. After all samples have been plated, plate was 
centrifuged at 4000RPM for 2min. Then, plate was ready to proceed to the protocol run. 
The protocol applied for FasR started with an initial incubation at 95°C for 5 min 
followed by 39 cycles at 95oC for 10s, 55,7oC for 10s and 72oC for 10s. In the case of DR5 
the protocol was 1 cycle at 95°C for 5 min, 9 cycles at 95oC for 10s, 55oC for 10s and 72oC 
for 10s. Target gene expression levels were normalized to housekeeping genes using the 
Ct method and Bio-Rad CFX manager software. 
 
TABLE 3.1Primers sequences used in QRT-PCR 
DR5 (forward) 5'-GCACTCACTGGAATGACCTC-3' 
DR5 (reverse) 5'-GCCTTCTTCGCACTGACAC- 3' 
FasR (forward) 5’-AGCTTGGTCTAGAGTGAAAA -3’ 
FasR (reverse) 5’-GAGGCAGAATCATGAGATAT -3’ 
GAPDH (forward) 5’-ACAGTCAGCCGCATCTTC-3’ 
GAPDH (reverse) 5’-GCCCAATACGACCAAATCC-3’ 
18S (forward) 5’-GAAGATATGCTCATGTGGTGTTG-3’ 
18S (reverse 5’-CTTGTACTGGCGTGGATTCTG-3’ 
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3.6 Evaluation of NK‐mediated killing 
 
3.6.1 Isolation of NK cells 
 
Freshly NK cells were isolated from peripheral blood mononuclear cells (PBMCs) 
from healthy donors by negative selection using the NK cell isolation kit (Miltenyi Biotec) 
according to the manufacturer’s protocol. Isolated NK cells were assessed for purity by 
flow cytometry using human anti-CD3 and CD56 monoclonal antibodies. 
NK cells were maintained in RPMI 1640 medium supplemented with 10% FBS and 
antibiotics as described above. For expansion and activation of NK cells, the culture 
medium was supplemented with 250 IU/ml recombinant human IL-2 (Peprotech) and 
100 IU/ml recombinant human IL-15 (Peprotech) at 37oC in a 5% CO2-95% air 
atmosphere.  IL-2 and IL-15 were added to NK cells on days 1 and 2 and then NK cells 
were used in killing assays. 
 
3.6.2 Concanamycin A inhibition assay 
 
Concanamycin A (CMA) is a potent and selective inhibitor of the 
perforin/granzyme cell death pathway in NK cells, which is the main pathway used by 
cytotoxic NK cells. To determine the functional contribution of the perforin pathway in 
fresh and IL-2 activated NK cells, NK cells were incubated with 10µM CMA for 20h before 
co-culture with target cells. CMA was kept in the medium during the experiment. The 
cytotoxicity of NK cells against tumor cells was performed after 4h co-culture using the 
chromium-51 (51Cr) release assay as described below in section 3.6.4.  
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3.6.3 Cytolytic activity of NK cells against tumor cells 
 
The cytolytic activity of NK cells against adherent and spheres was analyzed using 
the 51Cr release assay. This method has been considered the “gold standard” assay to 
accurately evaluate the NK cells cytotoxic activity against tumor cells. Chromium release 
assay is based on fact that NK cells exert cytotoxic mechanisms, which ultimately 
promote the disruption of cell membrane of 51Cr pre-labeled target cells, causing the 
release of the radioisotope to the surrounding medium. Thus, the 51Cr activity released 
to supernatants allows the quantification of cell death, compared to control conditions. 
For testing the effects of DOX and BTZ on cells’ susceptibility to NK cells, tumor 
target cells were pretreated with 10nM of BTZ or 0.05μM of DOX for 24h before 
incubation with NK cells. 
 
3.6.4 Chromium‐51 release assay 
 
A tumor cell suspension containing 1x106 cells/mL in 500µL RPMI medium was 
incubated with 50µCi of 51Cr (PerkinElmer) for 1h at 37oC. After the incubation period 
cells were washed twice to remove the unincorporated 51Cr and plated in a round-
bottom 96-MW (Orange Scientific) plate at a density of 5.000 cells/well and co-cultured 
with fresh or IL-2 activated NK cells in a effector:target  (E:T) ratio of 10:1. Cells were 
maintained in co-culture for 4h or 20h at 37oC. Afterwards plates were centrifuged and 
the supernatants were transferred to tubes and assayed for radioactivity in a 
radioisotope well counter (CRC-55tW Capintec®) within the 51Cr sensitivity energy 
window. 
The amount of radioactivity released in supernatant is taken as an indicator of 
the amount of lysis occurred. The percent specific lysis was calculated using the 
following formula: 
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ܵ݌݂݁ܿ݅݅ܿ	݈ݕݏ݅ݏ	(%) = ݐ݁ݏݐ	ݏܽ݉݌݈݁	ݎ݈݁݁ܽݏ݁ − ݏ݌݋݊ݐܽ݊݁݋ݑݏ	ݎ݈݁݁ܽݏ݁݉ܽݔ݅݉ݑ݉	ݎ݈݁݁ܽݏ݁ − ݏ݌݋݊ݐܽ݊݁݋ݑݏ	ݎ݈݁݁ܽݏ݁ × 100 
 
Spontaneous release represents 51Cr released from tumor cells in medium in the 
absence of NK cells and maximum release corresponds to 51Cr release from cells lysed in 
medium containing 4% SDS. 
 
3.7 Statistic 
 
 Statistical analysis was performed using GraphPad Prism 6.0 software (San Diego, CA). 
Data was presented as the mean ± standard error of the mean (SEM) of the indicated number of 
independent experiments (n). 
 The Mann-Whitney non-parametric test was performed for comparison of cells under 
different treatment conditions. The same test was used to compare between cell types 
maintained in the same conditions. 
 The one-way ANOVAtest with Dunnet’s correctionwas used for multiple comparisons 
between multiple samples under the same conditions. Results were considered statistical 
significant when p-value was lower than 0.05. 
 
 
.
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4.1 Bladder cancer cell lines contain sphere‐forming stem ‐like cells 
 
The isolation of CSCs from BC cell lines was performed using the sphere-forming 
assay that is a functional approach useful to retrospectively isolate and enrich potential 
CSCs subpopulations when specific surface markers are not identified. This assay relies 
on the ability of undifferentiated cells to proliferate and grow as spherical colonies in 
serum-free medium containing growth factors and supplements whereas more 
differentiated cells stop proliferating and die under these culture conditions. 
Both UM-UC3 and HT-1376 cell lines, when cultured in serum-free medium 
containing EGF, bFGF and B27, formed visible spherical colonies that continued to grow 
until day 10 reaching 50 µM diameter, which is indicative for the presence of a stem-like 
cell population in both cell lines.  Figure 4.1showed spherical colonies generated from 
single-cell suspensions of UM-UC3 and HT-1375 after 9 days. These cells, termed as 
CSCs, were further collected, gently dissociated and used in subsequent studies. 
 
 
FIGURE 4.1 BLADDER CANCER CELL LINES CONTAIN A POPULATION OF STEM-LIKE CELLS. 
UM-UC3 and HT-1376 cell lines (left panel) grew as monolayers in cell culture flasks with serum containing 
medium. Spherical colonies generated from single-cell suspensions of UM-UC3 and HT-1376 cells (right 
panel) cultured in a mixture of Matrigel and DMEM/F12 medium supplemented with EGF, bFGF and B27 
after 9 days. 
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4.2 Effect of doxorubicin in the viability of BC cell lines 
 
 
Since DOX is a chemotherapeutic agent highly cytotoxic against tumor cells, we 
performed a dose- and time -response study in both BC cells lines and corresponding 
CSCs. This assay was performed to determine the drug range concentrations to be used 
in further experiments, in which we will investigate the effect of DOX in the upregulation 
of death receptors in tumor cells, without affecting significantly the cell viability. 
 Both parental cells and corresponding CSCs were incubated with 0.025µM, 
0.5µM, 0.75µM and 0.1µM of DOX during 24h and 48h. Then, cell viability was evaluated 
using the MTT colorimetric assay.  
The dose-response curves of BC cell lines and their paired CSCs to DOX at 24h 
and 48h are shown in Figure 4.2. The incubation with DOX for 24h had practically no 
effects on cell viability nor in parental HT-1376 and UM-UC3 cells neither in 
corresponding CSCs.  
After 48h, it was observed a decrease in the percentage of viable cells mainly in 
the HT1376 cell line. The percentage of viable cells reaches the 70% when cells were 
incubated with 0.1µM DOX. For the UM-UC3 cell line,increasing the incubation period to 
48h did not affect significantly the cell viability over the range of DOX concentrations 
used. No significant differences were observed between parental and CSCs. 
These results showed that both BC cell populations are relatively tolerant to the 
DOX concentrations tested.  Based on this, we decided to test the effects of 0.05µM and 
0.1µM DOX during 24h or 48h on the regulation of death receptors at mRNA level in 
tumor cells. 
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Figure 4.2 Effects of doxorubicin in the viability of BC cell lines. 
Both UM-UC3 and HT-1376 cells and corresponding CSCs were incubated with varying concentrations of 
DOX for 24h or 48h.The percentage of viable cells was determined using the MTT colorimetric assay. 
Results were presented as mean ± SEM from three independent assays performed in duplicate. For 
statistical analysis, Mann-Whitney non-parametric test was applied to compare treated cells with a control 
condition. *p-value<0.05; **p-value<0.01; ***p-value<0.001 
 
 
4.3 Effect of bortezomib in the viability of BC cell lines 
 
 
Bortezomib (BTZ) was recently tested as the first proteasome inhibitor with anti-
tumor activity in hematological and solid tumors. We sought to determine the 
susceptibility of parental UM-UC3 and HT-1376 cell lines and corresponding CSCs to 
different concentrations BTZ ranging from 5nM to 20nM for up to 24h or 48h of 
incubation. The cell viability was evaluated using the MTT colorimetric assay. 
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 The effects of increasing concentrations of BTZ in cells’ viability at different 
incubation periods are shown in Figure 4.3. The treatment of HT-1376 cell lines with BTZ 
showed a significant decrease in cell viability for concentrations above 10 nM at 24h.  
At 48h of exposure the effects become more pronounced with a significant 
decrease being observed at the lowest tested concentration (5nM). The UM-UC3 cell 
line was relatively less sensitive to BTZ as compared with the HT-1376 cell line. Only for 
concentrations of 20nM at 24h it was observed a pronounced decrease in cell viability 
that was more pronounced at 48h post-incubation.  Similar to DOX viability assay, there 
was no significant difference between parental cells and CSCs.  
Taking these results into account, we decided to evaluate the effects the lower 
concentrations of BTZ (5nM and 10nM) during 24h or 48h on the mRNA expression 
levels of death receptors in parental and CSCs.  
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FIGURE 4.3 EFFECTS OF BORTEZOMIB IN THE VIABILITY OF BC CELL LINES. 
Both UM-UC3 and HT-1376 cells and corresponding CSCs were incubated with varying concentrations of 
BTZ for 24h or 48h. The percentage of viable cells was determined using the MTT colorimetric assay. 
Results were presented as mean ± SEM from three independent assays performed in duplicate. For 
statistical analysis, Mann-Witney non-parametric test was applied to compare treated cells with a control 
condition. *p-value<0.05; **p-value<0.01; ***p-value<0.001 
 
 
4.4 Constitutive expression levels of death receptors in adherent 
and corresponding CSCs 
 
Although some genes have been associated with parental or stem cells in several 
cancer types, the difference in death receptors expression between CSCs and non-CSCs 
is poorly understood. 
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To further evaluate whether CSCs might differ from parental cells in the 
expression levels of death receptors, we performed a quantitative qRT-PCR analysis for 
measuring the transcript levels of Fas and DR5 in spheres and adherent cells. The 
expression levels of target genes in each cell population were normalized to two 
housekeeping genes (GAPDH and 18S) and are expressed in arbitrary units.  
Fas and DR5 genes are constitutively more expressed in parental cells than in 
CSCs, with the exception of DR5 in the HT-1376 cell line, whose levels were similar in 
adherent and spheres. However, only the differences of Fas expression in UM-UC3 
achieve the statistical significance, as depicted in Figure 4.4. 
Overall, the death receptor Fas was constitutively more expressed (10- to 20-
fold) in the two tested BC cell lines than DR5. This higher expression of Fas mRNA 
relatively to DR5 was observed in parental cells as well as in sphere-forming cells. 
 
 
FIGURE 4.4qRT-PCR ANALYSES OF FAS AND DR5 IN PARENTAL AND SPHERES FROM UM-UC3 AND HT-1376 CELL LINES. 
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The mRNA expression levels of Fas and DR5 were normalized to two housekeeping genes (18S and 
GAPDH). The results are expressed in arbitrary units (AU) ± SEM from two independent assays performed 
in duplicate. For statistical analysis, t-student test was applied to compare CSCs with parental cells. *p-
value<0.05;  
 
4.5 Regulation of Fas and DR5 expression by DOX and BTZ 
 
 
Recent studies have demonstrated that some chemotherapeutic drugs have the 
ability to increase the surface expression of apoptosis-related receptors in some types of 
tumors. It has been proven that this effect could be due to a decrease of degradation 
rate and an upregulation of gene expression. 
We though to examined the effects of DOX and BTZ on mRNA expression of Fas 
and DR5 in two BC cell lines and in their corresponding CSCs, using a QRT-PCR assay. The 
results are shown in Figure 4.5. 
Both UM-UC3 and HT-1376 parental cells were incubated with two different 
concentrations of DOX (0.05µM and 0.1µM) and BTZ (5nM and 10nM) during 24h or 
48h, previously selected in sections 4.2 and 4.3, respectively. The selection of these 
concentrations was based on their small effects on cell viability.  
The mRNA expression levels of the two genes of interest, Fas and DR5, in pre-
treated cells were normalized to two housekeeping genes (GAPDH and 18S) and 
expressed as fold change relative to untreated control cells that were set as 1.  
We start by testing two different drug concentrations in parental cells. Both 
drugs induced a significant increase in the expression of Fas and DR5 mRNA levels 
relatively to control untreated cells. However this augment did not occur in a dose- or 
time-dependent manner. For instance, in parental cells the most pronounced increase in 
Fas expression was mostly achieved at 24h incubation with 0.05µM DOX, while the 
highest Fas upregulationwas observed using 5nM or 10nM BTZ in UM-UC3 and HT-1376 
cell lines, respectively. Increasing the incubation for 48h did not resulted in pronounced 
increments in Fas expression.  
Results 
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The death receptor DR5 that was expressed at very low levels in control 
conditions increased significantly after treatment with both drugs after 24h incubation 
and persisted or increased even more after 48h incubation. In both BC cell lines the 
highest upregulation of DR5 was observed when cells were treated with 0.05µM DOX for 
48h. The treatment with 10nM BTZ for 24h or 48h promotes the highest expression of 
DR5 gene in UM-UC3 cells and HT-1376, respectively. Based on these observations we 
selected two drug concentrations (0.05µM DOX and 10nM BTZ) for testing in CSCs.  
The effects of DOX or BTZ on death receptors expression in sphere-forming cells 
were not so pronounced. Any of the drugs exerted significant increments on Fas 
expression, with the exception of a significant upregulation in UM-UC3 cells treated with 
0.05µM DOX during 48h. The expression of DR5 gene in CSCs was significantly increased 
upon DOX and BTZ exposure being more marked after 48h.  
Taken together, these results suggest that sub-apoptotic doses of DOX and BTZ 
promote Fas and DR5 transcription in BC tumor cells. Moreover, bladder CSCs are less 
responsive to DOX and BTZ sensitizing effect, when compared to their corresponding 
parental cells. 
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FIGURE 4.5 EFFECTS OF DOX AND BTZ IN DEATH RECEPTORS FAS AND DR5 GENE EXPRESSION. 
mRNA expression levels of Fas and DR5 in parental and CSCs of UM-UC3 and HT-1376 cell lines, upon 
incubation with DOX (0.05µM and 0.1µM) and BTZ (5nM and 10nM) during 24h and 48h. The results are 
expressed as fold difference of the control (untreated cells) ± SEM. For statistical analysis, one-way 
Results 
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Kruskal-Wallis non-parametric ANOVA test with Dunnet’s correction was applied to compare expression 
levels of Fas and DR5 between treatment conditions. *p-value<0.05; **p-value<0.01; ***p-value<0.001 
4.6 Isolation of a highly purified NK cell population 
 
Purified NK cells were isolated from PBMCs of healthy donors using a commercial 
isolation kit, according to the manufacturer instructions. The purity of the resulting cell 
populations was checked by flow cytometry using a gated strategy. The gating strategy 
isshown in figure 4.6. Briefly, the lymphocyte population was identified based on 
forward (FSC) and side-scatter (SSC) parameters, which are indicators of relative particle 
size and complexity. Then single cells were selected examining the relative signal height 
vs. area of cells to exclude doublets. Subsequently, CD3+, CD14+ and CD19+ expressing 
cells representing T-cells, B-cells or monocytes, were excluded. Pure NK cells subset was 
selected based on a CD56+(dim)/CD16+or CD56+(bright)/CD16+/- profile. The isolated NK cell 
population purity was generally above 90%. 
 
FIGURE 4.6 GATING STRATEGY TO IDENTIFY NK CELLS SUBSET. 
Representative flow cytometry plots from the healthy donors blood to demonstrate NK cells gating 
strategy. NK cell subsets were isolated by sequentially gating on (a) lymphocytes, (b) single cells, (c) 
CD3/CD14/CD19- negativepopulation and finally (d) NK cells expressing CD56 and/or CD16. NK cell subsets 
were identified as CD56+(bright)/CD16- (upper left gate): and CD56+(dim)/CD16+. (upper right gate)  
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4.7 Inhibition of perforin killing pathway by concanamycin A 
 
It has been proven that NK cells exhibit two major killing pathways, namely the 
release of granules containing perforin and granzymes and activation of death receptors 
signaling on tumor cells by interaction with NK ligands. 
Since we intended to study exclusively the role of death receptors in NK-
mediated killing it was necessary to block the perforin-based cytotoxic activity of NK 
cells. There are some described compounds with the capacity to reduce the perforin 
content and inhibit the de novo synthesis in immune cells. Concanamycin A (CMA) has 
been extensively used as a selective inhibitor of perforin-mediated cytotoxicity in 
immune cells. Importantly, previous studies have demonstrated that CMA does not 
affect the expression and cellular localization of Fas ligand or TRAIL107. 
Previous studies demonstrate that the perforin pathway is the major NK cells 
killing mechanism occurring in earlier phases while death receptors killing pathway take 
place predominantly at later time points. To confirm whether CMA inhibits the perforin-
mediated killing, we measured the lytic capacity of untreated or CMA treated NK cells in 
a short-term cytotoxic assay using the UM-UC3 cell line. 
Briefly, tumor cells were labeled with 51Cr isotope for 1 h and then co-cultured 
with NK cells in a E:T ratio of 10:1. To block perforin killing pathway, NK cells were 
incubated with CMA for 2h before the co-culture with tumor cells. After 4h cells-free 
supernatants were collected and measured in a gamma counter for 51Cr activity. This 
study was performed with fresh NK cells and with 24h IL-2-activated NK cells. 
As expected, fresh NK cells exhibited a weak cytolytic activity against tumor cells, 
being not significantly affected by pre-treatment with CMA. When we used NK cells 
previously stimulated with IL-2 for 24h, these immune cells became more able to induce 
lysis in tumor cells, than freshly isolated cells. Moreover, the inhibition of perforin 
activity with CMA almost abolished the lysis of tumor cells by NK cells as indicated by the 
51Cr-release assays in Figure 4.7 
 These results indicate that inhibition of perforin/granzyme-mediated pathway 
with CMA strongly inhibits cytolytic activity of IL-2-activated NK cells against tumor cells. 
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In contrast, pre-treatment with CMA had no significant effect on the lytic activity of 
fresh NK cells, suggesting fresh NK cells have low lytic ability mediated by 
perforin/granzyme pathway, probably due to low expression of activating receptors on 
their surface. Moreover, CMA appears to be an important tool to distinguish the 
contribution of each cytolytic pathway to NK cells killing. 
 
 
FIGURE 4.7 INHIBITION OF PERFORIN/GRANZYME PATHWAY BY CMA IN NK CELLS 
Tumor cells were labeled 51Cr for 1h and then incubated with NK cells in a 4h cytotoxic assay in a E:T ratio 
of 10:1. Fresh and IL-2 stimulated NK cells were pre-treated with CMA for 2h before the co-culture to 
deplete perforin. Apoptotic cell death was calculated by collecting the cells supernatants and measuring 
their 51Cr activity in a gamma counter. The experiment was performed in duplicate. 
 
 
4.8 Pre‐treatment with DOX or BTZ sensitize BC cells to fresh NK‐
mediated cytotoxicity 
 
To verify whether upregulation of cell death receptors sensitizes BC cells to NK-
mediated killing NK cells, we next performed a 51Cr-release assay against BC cell lines 
pre-treated with sup-apoptotic doses of DOX and/or BTZ. 
Since NK cells are capable of using death receptors ligands to induce cytotoxicity 
in the absence of perforin, we measured the effects of DOX (0.05µM) and/or BTZ (10nM) 
in death receptors-mediated killing using fresh NK cells and a long-term cytotoxicity 
assay. To address this, both parental and CSCs were treated with 0.05µM DOX and/or 
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10nM BTZ during 24h before the 20h co-culture with freshly isolated NK cells.  To test 
exclusively the influence of death receptors signaling in NK antitumor response, NK cells 
were incubated with 10nM CMA immediately before the co-culture with tumor cells. 
The results presented in Figure 4.8, demonstrated that fresh NK cells exert a 
weak anti-tumor activity, causing less than 10% of lysis either in both BC parental cell 
lines as well as in corresponding CSCs, under controls conditions. Pre-treatment with 
DOX, BTZ or both drugs in combination induced a significant increase in the killing 
activity of NK cells against parental cells that reached nearly 50% of tumor lysis. Only 
10% of cell death was elicited by drug side-effects. No significant effects were observed 
in the % cell lysis between cells treated with DOX or BTZ. 
In contrast, pre-treatment of CSCs with DOX, BTZ or both during 24h did not 
increase significantly their susceptibility to the anti-tumor activity of NK cells. Overall, 
the small increase observed in lysis rate of CSCs in relation to untreated control cells, is 
mainly caused by the drug-side effects and not by the NK-mediated killing, as depicted in 
Figure 4.8. 
Remarkably, the addition of CMA to NK cells did not significantly affect their 
capacity to kill tumor cells in a long-term assay using fresh NK cells, suggesting that 
death receptors-mediated pathway compensate the lack of perforin-dependent 
pathway to induce cytotoxicity. 
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FIGURE 4.8 PRE-TREATMENT WITH DOX AND BTZ SENSITIZES PARENTAL BC CELL LINES BUT NOT CSCS TO NK-
MEDIATED KILLING. 
Fresh NK cell killing of UM-UC3 and HT-1376 parental cells and their corresponding CSCs in a 
20hr 51Cr release assay, using a E:T ratio of 10:1. Results were presented as mean ± SEM from 
two independent assays performed in duplicate. For statistical analysis, t-student test was 
applied to compare treated cells with a control condition. *p-value<0.05; **p-value<0.01; 
 
 
4.9 Pre‐treatment with DOX or BTZ sensitize BC cells to IL‐2‐
stimulated NK‐mediated cytotoxicity 
  
It has been suggested that IL-2 stimulation promotes an increase in NK cells lytic 
activity, in part due to the upregulation of FasL and TRAIL, ligands to Fas and DR5 
receptors on tumor cells, making them more able to kill tumor cells than freshly isolated 
NK cells108,109.  
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 Taken this into account, we considered to test whether the increase levels of 
death receptors ligands on NK cells promote a greater tumor killing through death 
receptors signaling.  
 To address this, NK cells were incubated with 250 IU/mL of IL-2 for 24h before 
the co-culture with tumor cells, which is carried out for 20h. Once again, 10nM of CMA 
was added to NK cells before the co-culture with tumor cells in order to inhibit the 
formation of perforin/granzyme granules and, subsequently their release to the 
medium. This study was only performed with the parental UM-UC3 cell line 
 IL-2-activated NK cells revealed higher cytotoxicity activity than fresh NK cells 
(observed in figure 4.8) even when the perforin pathway was blocked with CMA. As we 
observed with fresh NK cells, pre-treatment with DOX and BTZ also improved the anti-
tumor response of IL-2-stimulated NK cells through death receptors signaling pathway. 
When tumor cells were treated with drugs during 48h, it was observed a slightly 
increase in the percentage of lysed cells resulting from the direct effects of drugs on 
tumor cells as well of the cytolytic activity of NK cells.  
  
 
 
FIGURE 4.9 PRE-TREATMENT WITH DOX OR BTZ SENSITIZES UM-UC3 CELLS TO IL-2-ACTIVATED NK-MEDIATED KILLING 
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IL-2 –activated NK cells were co-cultured withUM-UC3 cells pre-treated with 0.05µM or 5nM for 24h or 
248h with a E:T ratio of 10:1.  The % of specific lysis were determined using the 51Cr-release assay after 
20h of co-culture. To block of perforin-mediated cytotoxicity, NK cells were pre-treated with 10nM of 
CMA. This experiment was performed once, in duplicate. 
 
4.10 Expression levels of Fas and DR5 in bladder cancer specimens 
 
Although death receptors have been proven to play an important role in tumor 
killing by immune cells, their variation of expression in BC is poorly known. Hence, we 
though to evaluate the association between mRNA levels of apoptosis-related receptors 
and the tumor stage in BC. 
With this intend, we used mRNA isolated from 14 clinical samples of BC patients 
collected during TUR. These tumors were classified by a clinical pathologist as non-
invasive low grade (n=3), non-invasive high grade (n=7) and muscle invasive (n=4). Then, 
mRNA was reverse transcribed into complementary DNA in order to perform the qRT-
PCR technique. The expression levels of target genes were normalized to two 
housekeeping genes and expressed as arbitrary units (Figure 4.10).  
Our results showed that both Fas and DR5 genes transcripts are constitutively 
expressed in BC samples, and exhibit a similar expression pattern among the set of 
samples analyzed. Despite the few number of cases studied, there is evidence of an 
increase of death receptors with the tumor stage. The expression levels of  death 
receptors are lower in low grade non-muscle invasive tumors and increased 
progressively with the tumor stage, being higher in the muscle-invasive tumors, which 
are associated with a poor prognosis.  
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FIGURE 4.10FAS AND DR5 MRNA EXPRESSION IN BLADDER CANCER CLINICAL SAMPLES ACCORDING WITH THE TUMOR 
STAGE. 
Expression of Fas and DR5 was normalized to housekeeping genes, namely 18S and GAPDH. Results are 
expressed as mean ± SEM. For statistical analysis, one-way ANOVA test was applied to compare Fas and 
DR5 expression among BC stages. (*P<0.01, ****P<0.0001 
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 In this work, we aimed to enhance the efficacy of a NK-based therapy against BC 
cell lines through upregulation of death receptors Fas and DR5 induced by treatment 
with sub-apoptotic concentrations of DOX and BTZ. 
 
Bladder cancer is the one of the most common cancers in the world, being 
present in one of two forms, namely superficial and muscle-invasive tumors. The former, 
often with a good prognosis have a high propensity to relapse and to progress into 
muscle-invasive forms with an overall poor prognosis14.  Indeed, increased tumor 
invasiveness is associated with poor patients’ outcomes29,67. A highly tumorigenic 
population of cells, named CSCs, has emerged as key drivers of carcinogenesis and 
tumor progression in BC as well as in other types of malignancies110. 
 Chemotherapy remains a first-line treatment for BC advanced stages, however 
recent evidences demonstrate that standard chemotherapy regiments promote a CSCs 
enrichment, by survival of chemoresistant clones and active production of PGE2, which 
induces the proliferation of bladder stem-like cells111,112. 
 Therefore, new therapeutic approaches are needed to eliminate all tumor cell 
populations. In this context, cancer management has dramatically changed over the past 
decades, from conventional cytotoxic agents that nonspecifically kill tumor cells,to 
targeted therapies designed to interfere with specific molecules or pathways that are 
required to tumor cells growth113.   
With the advanced knowledge of immunology, immunotherapy has become a 
promising and effective modality to fight cancer. Indeed, the ability of several immune 
cells, like NK cells, to recognize and kill tumors is well documented. Several advantages 
to use NK cells as immunotherapeutic agents rather than other immune cells have been 
described, including their antigen-independent response capacity and their simple 
isolation and expansion method78.  
Unfortunately, tumor cells may develop strategies to evade the NK-mediated 
killing by increasing expression of MHC-I or anti-apoptotic proteins, avoiding NK 
recognition and protecting apoptosis activation,or establishing an immune-privileged 
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environment impairing NK functions.To counterbalance this phenomenon, several 
strategies have been developed to enhance NK cells anti-tumor efficacy, improving 
antigen presentation, inhibiting tumor-mediated immunosuppression and sensitizing 
tumor cells to NK-mediated killing106,113,114. 
We focused our attention on the ability of some chemotherapeutic agents to 
induce an upregulation of death receptors genes in BC tumor cells, which can lead to an 
increase in NK anti-tumor response efficiency. Gene expression of death receptors has 
been assessed in several tumor cell types upon incubation with several drugs, such as 
Ibuprofen, melatonin, etoposide, DOX and BTZ among others85-89. Owing to their ability 
to upregulate death receptors expression in other malignancies, we chose to test the 
effects of DOX and BTZ in BC cell lines.  
The cell lines used in this study (UM-UC3 and HT-1376) were both established 
from tumor samples of patients diagnosed with muscle-invasive TCC. Despite displaying 
different cell morphology and growth rate, they respond similarly to the 
chemotherapeutic agents cisplatin and methotrexate (unpublished data). We have 
successfully isolated a population of stem-like cells from both UM-UC3 and HT-1376 cell 
lines using the sphere-forming assay.  Indeed, previous experiments performed in our 
lab (submitted for publication) showed these cells express pluripotent stem cell markers 
(SOX2, Nanog and Oct4), basal urothelium surface markers (CD44 and KRT14) and 
exhibited a chemoresistant phenotype to chemotherapeutic agents used in the 
treatment of invasive BC, which fulfills the criteria for functional CSCs. 
We started to evaluate the constitutive expression levels of Fas and DR5 in both 
BC cell lines and in their corresponding CSCs using the QRT-PCR technique. Our results 
showed that both death receptors are constitutively expressed in BC cell lines. However 
the expression levels of DR5 are considerably inferior to that of Fas. The expression 
levels of Fas in both parental cells were confirmed at protein levels by flow cytometry 
(data not shown). Additionally, Królh et al. confirmed the DR5 surface expression on 
other BC cell lines (SW780, 647V, T24) using the same method of detection 90. 
Remarkably, we demonstrate for the first time that both death receptors 
aredown-regulated in CSCs population when compared to their parental cells; 
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however,statistical significance only was achieved for Fas gene in UM-UC3 cells. These 
results suggest a novel mechanism of CSCs resistance to prevent the attack of immune 
system by NK cells and consequently cell death. Other mechanisms of CSCs to escape 
from immune cells have been described, namely down-regulation of MHC-I, a receptor 
responsible for antigen presentation, preventing the T-cell mediated recognition115.  
Before examining the effects of DOX and BTZ on regulation of death receptors 
genes, we first analyzed the dose- and time-dependent effects of both agents in the 
viability of BC cells using a MTT colorimetric assay. This assay measures the 
mitochondrial activity, which is intrinsically related to the number of viable cells. With 
this experiment, we intended to determine the concentrations of DOX and BTZ that 
cause a small reduction in cell viability to be used in subsequent studies. 
To address this, cells were incubated with DOX and BTZ for 24h or 48h in a 
concentration range of 0.01-0.1µM and 5-20nM, respectively. Results demonstrated 
that BC cells are relatively tolerant to DOX concentrations tested, and more susceptible 
to BTZ especially the HT-1376 cells. Since BTZ is a potent proteasome inhibitor, its 
sensitivity on BC lines might at least in part be due to the accumulation of misfolded 
proteins that promote the misfolded protein response, leading to apoptosis activation 
92. Moreover, previously literature also suggests that the proteasomal inhibition induces 
ER stress, causing calcium release. Consequently, the mitochondrial uptake of calcium 
leads to cytochrome c release, followed by Bid cleavage, resulting in activation of 
apoptosis system 93. 
Based on theresultsobserved, we decided to test the effect on 0.05µM and 
0.1µM of DOX and 5nM and 10nM of BTZ in the regulation of Fas and DR5 genes 
expression, since under these concentrations cell viability was not reduced below 70%. 
The transcripts levels of each death receptors after DOX and BTZ treatments in parental 
cells and their corresponding CSCs, were measured using the QRT-PCR technique.  
We observed a considerable and significant increase of each receptor expression 
in both cell lines upon treatment with DOX and BTZ that varied with concentrationand 
period incubation. Overall, the maximal expression of Fas in parental cellswas 
observedafter 24h incubation with 0.05µM DOX or 10nM BTZ incubation while maximal 
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increaseof DR5 was observed with higher drug concentration or longer incubation times. 
The mRNA levels of DR5, whose basal expression levels were very low, increased at 
much higher extent than Fasin response to drugs treatment in both BC cell lines. 
The mechanisms by which DOX and BTZ upregulate death receptors appear to be 
complex. Doxorubicin and BTZ trigger the activity of c-Jun N-terminal kinase (JNK), which 
in turn enhances the activation of the tumor suppressor p53116,117. Subsequently, p53 
migrates to the nucleus and binds to elements within the promoters and intronic 
sequences of Fas and DR5 genes, inducing gene expression118,119.  
In addition to promoting death receptors transcription, DOX and BTZ influence 
the levels of death receptors by stimulating the association of mRNA stabilizing factor 
HuR protein to 3’UTR of death receptors transcripts, increasing their half-life and 
stimulating trafficking from the Golgi to the membrane in a p53-dependent 
manner118,120. 
In contrast, DOX and BTZ treatments slightly induced an upregulation of Fas as 
well as DR5 in CSCs populations, with greater increases being observed in 48h 
treatments. This is likely due to the fact that CSCs populations frequently exhibit 
mutations in p53 gene, which plays a crucial role in the transcription of death receptors, 
as explained above. Strictly, several reports have demonstrated a correlation between 
tumors with p53 mutations and their undifferentiated phenotype, suggesting that p53 
mutations are major players in the formation of the CSCs population119.Moreover, p53 
mutations have been widely associated with increase tumor aggressiveness and 
progression in several types of malignancies119.  
Nevertheless, Virseda-Rodriguez et al. observed numerous point mutations in 
p53 gene in BC patients, responsible for genetic instability and alterations in p53 
function, implying p53 mutations in tumor progression and invasiveness. Higher doses or 
longer exposure times to chemotherapeutic agents might induce a greater expression of 
death receptors, however this could compromise the CSCs viability121. 
While BTZ has been described as a cancer-specific agent not affecting normal 
cells, DOX is very cytotoxic and commonly affects normal and tumor cells122,123. In fact, 
the studies of Fernandez et al.have demonstrated that BTZ selectively induces the 
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expression of apoptosis-related proteins, such as NOXA, in tumor cells but not in normal 
cells124.  However, the selective upregulation of death receptors by BTZ is yet to be 
demonstrated. Nevertheless, their possible unspecific effects in death receptor 
regulation should not affect the viability of normal cells, since NK cell-mediated 
cytotoxicity depends on a previous tumor cell recognition by these immune cells, which 
is independent of death receptors expression. 
Considering the previous results, we decided to test the effects of 0.05µM DOX 
and 10nM BTZ during 24h in the sensitization of tumor cells to NK-mediated killing, using 
the long-term 51Cr release assay. To perform this, 51Cr-loaded tumor cells were co-
cultured with NK cells for 20h in a E:T of 10: 1. This ratio was selected within a range of 
effector/target proportions previously tested between 1:1 and 1:10. The 10:1 ratio was 
the one with high lytic efficiency and was selected to our studies. This technique allows 
the measurement of the 51chromium activity in the supernatant, which is an indicator of 
the amount of lysis occurred in target cells. 
The cytolytic activity of NK cells against BC cells pre-treated with DOX or BTZ 
wastested using a long-term assay in alternative to the classical short-term assay of 4h 
that measures perforin/granzyme-mediated cell death pathway, which is the 
predominant pathway used by NK cells. The co-cultures were maintained for 20h since 
death receptor-mediated cell killing occurredat later time points. Moreover a long-term 
assay may better represent the in vivo potential and anti-tumor capacities of NK cells, 
allowing the observation of several lytic pathways. 
We focused our attention on the cytotoxic activity of fresh NK cells due to the 
fact that IL-2 stimulation induces the gene expression of perforin and granzymes genes, 
increasing the perforin and grazymes content125. Thus, it is expected that in assays 
where target cells are surrounded by perforin-enriched NK cells the effects of death 
receptors-mediated killing would not be observed. Additionally, we measured the 
surface expression levels of Fas ligand on NK cells, which engages with Fas receptor on 
tumor cells, upon 48h IL-2 stimulation and we did not observed a significant increase in 
NK stimulated cells (data not shown). 
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To avoid the contribution of the perforin/granzymes pathway on NK cells-
mediated cell death, NK cells were pre-treated with 10nM CMA. This agent prevents 
perforin-based cytotoxicity by increasing pH inside of perforin-containing vesicles, 
leading to the enzymatic degradation without affecting death receptors ligands107. The 
inhibitory effect of CMA was confirmed in a 4h 51Cr release assay, in which it was 
observed a decrease in the lytic activity of stimulated NK cells treated with CMA, 
suggesting the cytotoxicity of IL-2 stimulated NK cells dependson perforin content. On 
the other side, the cytolytic activity of fresh NK cells was very low and appears to be 
independent of perforin, since we did not observed a significant decrease in the cytolytic 
activity of NK cells after treatment with CMA. 
Results from long-term cytotoxic assay using fresh NK cells revealed that pre-
treatment of tumor cells with DOX and BTZ augments significantly the NK cells anti-
tumor response, resulting in a significant increase of tumor lysis as a consequence of the 
upregulation of death receptors. We cannot exclude the contribution of other 
mechanisms beside death receptors upregulationto the increase cell death of target 
cells. In fact, previous studies have demonstrated that DOX and BTZ influence the 
expression of other apoptosis-related proteins, increasing the expression of pro-
apoptotic molecules, such as caspase-8 and Bid, and/or reducing expression of anti-
apoptosis elements, like Bcl-XL and c-FLIP. 
Furthermore, previous reports suggest that engagement death receptors to their 
respective ligands on NK cells can also induce an even higher expression of death 
receptors on tumor cells and, consequently a more efficient NK cells-mediated killing. 
The drugs by themselves also contribute to an increase in cell death despite the low 
concentrations we used. The fact the cells remained in culture for an additional 20h 
(following 24h drugs incubation) during the long-term assay might explain the percent of 
lysis that was observed. 
Since death receptors signaling is one of the two major killing pathways,acting 
hand in hand with perforin/granzymes mechanism, it is likely that effect in tumor lysis 
when perforin is depleted is mainly due to Fas and DR5 activation. However, recent 
studies suggest the possibility that both chemotherapeutic agents studied promote an 
augment in cytokines production (IFN-γ) by NK cells, causing cell death by other killing 
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pathway126,127. Interestingly, the Fas-mediated killing is apparently dependent of IFN-
γ128. 
These results are in line with previous studies that demonstrated the increase in 
tumor killing with DOX and BTZ in several types of tumors. Indeed, Mizutani et al. has 
demonstrated that DOX can sensitize BC cells to lysis, an effect mediated by peripheral 
blood lymphocytes (PBL) and tumor infiltrating lymphocytes (TIL)129. 
It was also shown that the combination of several chemotherapeutic agents 
causes similar effects to DOX and BTZ treatment alone. This fact is likely to be due to the 
redundant mechanisms by either DOX or BTZ cause death receptors upregulation. 
In CSCs, we observed an increase of tumor lysis, an effect that was mainly caused 
by exposure to chemotherapeutic agents and not by NK cells. In fact the percent of 
tumor cell lysis resulting from NK cells killing activity did not change significantly in 
comparison to the control condition. These results can be explained by the 
slightlyupregulation of both death receptors induced by the concentrations of DOX and 
BTZ we used. In this experiment CSCs were pre-treated with 0.05µM DOX and/or 10nM 
BTZ during 24h, which were the same conditions we used in parental cells. These 
experimental conditions were less effective in upregulating death receptors in CSCs than 
that seen for parental cells. Future studies using increased drug exposure testing will be 
required to clarify this hypothesis. 
We conducted another experiment in which we used IL-2 activated NK cells to 
further evaluate whether upregulation of death receptors in tumor cells improve the 
antitumor activity of activated NK cells. This assay was performed only with one cell line 
(UM-UC3).  We observed that DOX and BTZ treatments (alone or in combination) 
improve the anti-tumor response of NK cells, as occurred when we used resting NK cells. 
Nevertheless, since IL-2 activated NK cells are intrinsically more cytotoxic than resting 
NK cells, the relative changesobserved in lysis activity versus control conditions were 
higher when we used freshly isolated NK cells.   
Once we proved that death receptors play an important role in anti-tumor 
response of NK cells, we tested the expression levels of both death receptors, using 
samples from dissected material of 14 BC patients in a qRT-PCR experiment. The clinical 
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samples were classifiedby a pathologist in non-invasive low grade, non-muscle-invasive 
high grade and muscle-invasive. Surprisingly, the results revealed a progressive increase 
in the expression of both death receptors transcripts with the tumor stage, being higher 
in muscle-invasive tumors with poor prognosis. Studies performed in other types of 
malignancies, such as breast, renal carcinoma or non-small lung cancer, also 
demonstrated the same tendency regarding DR5 expression130–132. On the contrary, a 
study performed in BC samples correlated DR5 protein levels with a better prognosis133. 
This discrepancy might be explained by the fact that we measured DR5 at mRNA level, 
while this study measured DR5 at protein levels and their distribution within BC cells. 
Moreover, recent reports demonstrated the presence of DR5 receptors in cytosolic and 
nuclear compartments, besides the plasma membrane, where they trigger apoptosis 
signaling134. Although the functions of intracellular DR5 remain unclear, a correlation of 
apoptosis resistance with intracellular presence of DR5 in breast cancer cells was also 
proposed in a study from Zang et al.135. 
Moreover, the role of Fas in tumor cells apoptosis has been a subject of intense 
debate, with some studies suggesting a pro-survival function, in contrast to others that 
propose a pro-apoptosis action136,137. Ultimately, the role of Fas in cancer regression or 
progression is related with cellular localization and types of tumor cells. A mechanism of 
alternative splicing during transcription of Fas gene generates a soluble form of Fas 
(sFas), which antagonizes the function of Fas on the plasma membrane. In fact, Yajima et 
al. related the levels of sFas in advanced stages of gynecological 
malignancies138.Therefore, it would be important to evaluate the cellular distribution of 
both death receptors and associate them with BC stage 
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In this study we proposed to explore an alternative therapeutic approach to BC 
treatment, using cytotoxic agents to improve the NK cells immune response against 
cancer cells (parental and CSCs). Therefore, the main goal of this work was to evaluate 
the effect of low concentrations of DOX and BTZin sensitizing human BC cells to NK cells-
mediated killing by inducing death receptors (Fas and DR5) expression. 
Our results provide evidence that NK cells antitumor response can be enhanced 
by a previous exposure of tumor cells to sub-apoptotic concentrations of DOX and BTZ, 
as a result of an upregulation of death receptors mainly in differentiated parental tumor 
cells. The CSCs population exhibited low basal levels of death receptors and were less 
sensible to an upregulation induced by DOX and BTZ, becoming less sensitive to NK-
mediating killing. Additionally, the expression of death receptors in BC was associated 
with tumor stage and aggressiveness, suggesting that they might be used as a prognostic 
marker in BC. 
Altogether, these results suggest that DOX and BTZ pretreatment might be used 
to enhance the efficacy of NK cells-based therapies, improving clinical outcomes. 
In future experiments we intend to evaluate the effect of higher concentrations 
and longer exposure times of DOX and BTZ in sensitizing the CSCs population to death 
receptors-mediated killing. Furthermore, we are interested in knowing the contribution 
of each receptor individually to NK-mediated tumor cell lysis, by blocking individually 
TRAIL and FasL on NK cells surface.  
Additionally, we aim to explore the effects of DOX and BTZ in the regulation of 
apoptosis-related proteins, either pro- and anti-apoptotic molecules, as well as in other 
NK cells killing pathways, like perforin and IFNγ mechanisms. Results from both 
experiments would provide new insights into DOX and BTZ-induced effects in sensitizing 
tumor cells to NK cells-mediated killing. 
Lastly, giving the interesting results we observed in BC cell lines, the next step 
will be to perform this therapeutic approach in in vivo studies in an animal modelBC. 
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